



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>C12N 15/11, A61K 31/70, C07H 21/00 //</b> <b>A61K 9/127, A61M 25/10</b>	<b>A2</b>	<b>(11) International Publication Number:</b> <b>WO 99/07844</b> <b>(43) International Publication Date:</b> 18 February 1999 (18.02.99)
<b>(21) International Application Number:</b> PCT/US98/16569 <b>(22) International Filing Date:</b> 7 August 1998 (07.08.98) <b>(30) Priority Data:</b> 60/054,967 7 August 1997 (07.08.97) US <b>(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application</b> US 60/054,697 (CIP) Filed on 7 August 1997 (07.08.97) <b>(71) Applicant (for all designated States except US):</b> THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health [US/US]; Suite 325, 6011 Executive Boulevard, Rockville, MD 20852-3804 (US). <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> MUKHERJEE, Anil, Baran [US/US]; 21120 Georgia Avenue, P.O. Box 136, Brookeville, MD 20833-0136 (US). KUNDU, Gopal, Chandra [IN/US]; Apartment #1812, 1001 Rockville Pike, Rockville, MD 20852 (US). PANDA, Dibyendu, Kumar		[IN/CA]; Apartment #20, 3721 Dupuis, Montreal, Quebec 83T 1E5 (CA). <b>(74) Agents:</b> CARROLL, Peter, G. et al.; Medlen & Carroll, LLP, Suite 2200, 220 Montgomery Street, San Francisco, CA 94104 (US). <b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). <b>Published</b> <i>Without international search report and to be republished upon receipt of that report.</i>
<b>(54) Title:</b> METHODS AND COMPOSITIONS FOR TREATMENT OF RESTENOSIS		
<b>(57) Abstract</b> <p>The present invention provides sequences capable of inhibiting osteopontin (OPN) expression. In particular, the sequences provided herein are antisense osteopontin oligonucleotide sequences. The present invention further provides methods for treating restenosis using antisense osteopontin oligonucleotide sequences. In particular, methods for treating restenosis following vascular surgery (e.g., percutaneous transluminal coronary angioplasty (PCTA) and directional coronary atherectomy (DCA)) by using antisense osteopontin oligonucleotide sequences are provided.</p>		

***FOR THE PURPOSES OF INFORMATION ONLY***

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

## METHODS AND COMPOSITIONS FOR TREATMENT OF RESTENOSIS

This work was made with Government support by the National Institutes of Health. The Government has certain rights in this invention.

### FIELD OF THE INVENTION

5           The present invention provides sequences capable of inhibiting osteopontin (OPN) expression. In particular, the sequences provided herein are antisense osteopontin oligonucleotide sequences. The present invention further relates to methods for treating restenosis using antisense osteopontin oligonucleotide sequences, and in particular, to treating restenosis following vascular surgery.

### 10       BACKGROUND OF THE INVENTION

Atherosclerosis (for review see Ross, R. (1993) *Nature* 362:801-809 and Hajjar *et al.*, (1995) *Amer. Scientist* 83:460-467) is the principal cause of heart attacks, stroke, gangrene and loss of function of extremities. It accounts for approximately 50% of all mortalities in the USA, Europe and Japan (Ross, R. (1993) *Nature* 362:801-809).  
15       The present therapeutic strategies for severe atherosclerosis in coronary arteries rely on angioplasty procedures (*e.g.*, percutaneous trans-luminal coronary angioplasty (PTCA), directional coronary atherectomy (DCA) or related angioplasty procedures), and coronary artery bypass surgery. For example, PTCA is the primary treatment modality in many patients with coronary heart disease. PTCA can relieve myocardial ischemia  
20       in patients with coronary artery disease by reducing lumen obstruction and improving coronary bloodflow.

While the use of interventional procedures has grown rapidly, reocclusion (or restenosis) of arteries is a serious complication which occurs in 30-50% of patients undergoing various angioplasty procedures within 3 days to 3 months. Restenosis  
25       results in significant morbidity and mortality and frequently necessitates further interventions, such as repeat angioplasty or coronary bypass surgery.

Although the processes responsible for restenosis are not completely understood, restenosis has been suggested to occur, at least in part, as a result of local inflammation, thrombosis and smooth muscle cell migration (Ferrell *et al.* (1992) Circulation 85:1630-1631) and proliferation (Austin *et al.* (1985) J. Am. Coll. Cardiol. 6:369-375; Giraldo *et al.* (1985) Arch. Pathol. Lab. Med. 109:173-175) within the intima of coronary arteries. To date, no post-angioplasty treatment has proven effective in the prevention or treatment of restenosis.

Thus, there is a need for methods and compositions for preventing and/or treating restenosis. Preferably, these methods and compositions are specific in their effect, easy to administer, and are effective over a short period of administration with minimal adverse side-effects.

## SUMMARY OF THE INVENTION

The present invention discloses novel osteopontin antisense sequences which are useful for the treatment and prevention of restenosis. The present invention further discloses methods of diminishing osteopontin expression in a subject capable of developing restenosis in a tissue, methods of treating restenosis in a subject suspected of being capable of developing restenosis in a tissue, methods of reducing osteopontin expression in a subject undergoing angioplasty, methods of treating restenosis in a subject undergoing angioplasty, and methods of detecting restenosis in a subject.

In particular, the invention provides an antisense sequence comprising a nucleic acid sequence complementary to at least a portion of the human osteopontin cDNA polynucleotide listed herein as SEQ ID NO:15. While it is not intended that the present invention be limited to any particular antisense sequence, in one preferred embodiment the antisense sequence is selected from the group consisting of SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, and SEQ ID NO:13. In addition, though the present invention is not limited to a particular type of linkage, in a more preferred embodiment, the antisense sequence comprises one or more phosphorothioate linkages. In a yet more preferred embodiment, the antisense sequence is entrapped in a liposome.

The present invention also provides pharmaceutical compositions comprising a pharmaceutically acceptable excipient and an antisense sequence comprising a nucleic acid sequence complementary to at least a portion of the polynucleotide of SEQ ID NO:15.

5 Further provided by the instant invention are methods of diminishing osteopontin expression, comprising: a) providing: i) a subject suspected of being capable of developing restenosis in a tissue; and ii) an osteopontin antisense sequence complementary of at least a portion of the polynucleotide of SEQ ID NO:15; and b) administering an amount of the sequence to the subject under conditions such that the  
10 osteopontin expression is diminished.

Without intending to limit the present invention to any particular subject, in one embodiment, the subject is undergoing angioplasty. Also without limiting the invention to a particular surgical method, in a more preferred embodiment, the angioplasty is selected from the group consisting of percutaneous trans-luminal  
15 coronary angioplasty and directional coronary atherectomy.

In an alternative embodiment, and without limiting the invention to a particular type of tissue, the tissue is coronary vascular tissue. In a preferred embodiment, the coronary vascular tissue is arterial.

In yet another alternative embodiment, without intending to limit the invention  
20 to a particular sequence, the osteopontin antisense sequence is selected from the group consisting of SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12 and SEQ ID NO:13.

Although it is not intended that the present invention be limited to a particular method of administering, in a further alternative embodiment, the administering is  
25 parenteral. In a preferred embodiment, the parenteral administering is intraarterial (*i.e.*, to the artery which is subjected to angioplasty). In yet a more preferred embodiment, the intraarterial administering is by using a catheter. In a particularly preferred embodiment, the catheter is a double balloon catheter.

In yet another alternative embodiment, the osteopontin antisense sequence is  
30 entrapped in a liposome.

The instant invention further provides methods of treating restenosis, comprising: a) providing: i) a subject suspected of being capable of developing restenosis in a tissue; and ii) an osteopontin antisense sequence complementary to at least a portion of the polynucleotide of SEQ ID NO:15; and b) administering an amount of the sequence to the subject under conditions such that the restenosis is diminished.

The present invention further provides methods of reducing osteopontin expression in a subject undergoing angioplasty, comprising: a) providing: i) a subject undergoing angioplasty; and ii) an osteopontin antisense sequence complementary to at least a portion of the polynucleotide of SEQ ID NO:15; and b) administering an amount of the sequence to the subject under conditions such that osteopontin expression is diminished. In one embodiment, and without intending to limit the invention to a particular sequence, the osteopontin antisense sequence is selected from the group consisting of SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12 and SEQ ID NO:13. In a preferred embodiment, the osteopontin antisense sequence comprises one or more phosphorothioate linkages. In a more preferred embodiment, the osteopontin antisense sequence is entrapped in a liposome. In yet a more preferred embodiment, the administering is substantially contemporaneous with the angioplasty. In a particularly preferred embodiment, the administering is by using a catheter. In a most preferred embodiment, the catheter is a double balloon catheter.

The present invention also provides methods of treating restenosis in a subject undergoing angioplasty, comprising: a) providing: i) a subject undergoing angioplasty; and ii) an osteopontin antisense sequence complementary of at least a portion of the polynucleotide of SEQ ID NO:15; and b) administering an amount of the sequence to the subject under conditions such that restenosis is diminished.

Also provided by the present invention are methods of detecting restenosis in a first subject, comprising detecting a higher level of osteopontin in a first tissue of a first subject suspected of being capable of developing restenosis in a second tissue relative to a level of osteopontin in said first tissue of a second subject substantially free of restenosis in said second tissue. In one embodiment, the first tissue is selected

from the group consisting of blood and plasma. In a preferred embodiment, the first tissue comprises monocytes comprising the osteopontin. In a more preferred embodiment, the second tissue is coronary vascular tissue. In yet a more preferred embodiment, the coronary vascular tissue is arterial.

## 5 BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 shows the characterization of OPN expression in cultured CASCs. Figure 1A, *panel a*, shows expression by RT-PCR (upper two panels), and Western analysis (lower panel) in log-phase and confluent CASCs. Figure 1A, *panel b*, shows expression of OPN protein in semiconfluent CASCs by immunoprecipitation followed by Western blotting. Figure 1B, *panel a*, shows an autoradiogram of affinity cross-linked OPN in sub-receptor complex in subconfluent cultured CASCs. Figure 1B, *panel b*, shows the results of a OPN binding study

Figure 2 shows the effect of OPN on CASC (A) migration, (B) ECM-invasion, and (C) proliferation.

Figure 3 shows (A) the detection of OPN-mRNA by *in situ* hybridization in coronary atherectomy arterial tissue (*panels a and b*), and in normal coronary arteries (*panels c and d*); (B) the detection of OPN-mRNA by RT-PCR in normal coronary arteries (*panel a*), and in coronary atherectomy arterial tissue (*panel b*); (C) the detection of OPN protein by Western blot analysis in control (*panel a*) and coronary atherectomy tissues (*panel b*).

Figure 4 shows (A) Western blot analysis of OPN in plasma samples of normal controls (*panel a*) and atherectomy patients (*panels b, c, and d*); (B) densitometric analysis of plasma OPN bands from normal controls (C<sub>1-3</sub>), atherectomy patients before DCA (P); and atherectomy patients after 1-4 weeks of DCA.

Figure 5 shows the nucleotide sequence (SEQ ID NO:15) of a cDNA of human osteopontin. This sequence contains a 5' untranslated region of 67 bases, followed by 942 bases encoding 314 amino acids, and 415 bases of the 3' untranslated region.

Figure 6 shows the effect of "LIPOFECTIN" alone (control), or in the presence of OPN sense sequence SHOPN-P2 (SHOPN) or the antisense sequence ASHOP-P1 (ASHOPN) on the proliferation of human coronary artery smooth muscle cells.

5 Figure 7 shows the effect of transfection of CSMCs with "LIPOFECTIN" alone, or "LIPOFECTIN" containing different concentrations of S-oligonucleotide antisense sequence ASHOPN-P1 (ASHOPN) (SEQ ID NO:9) on OPN-protein production as determined by immunoprecipitation followed by Western blot analysis.

Figure 8 shows the nucleotide sequence (SEQ ID NO:16) and deduced amino acid sequence (SEQ ID NO:17) of rat osteopontin.

## 10 DEFINITIONS

The term "restenosis" refers to a recurrence of stenosis. The term "stenosis" as used herein refers to a narrowing of any canal in the circulatory system including, but not limited to, valves (*e.g.*, aortic stenosis which involves narrowing of the aortic valve orifice), coronary arteries (*e.g.*, coronary ostial sclerosis which involves narrowing of the mouths of the coronary arteries), carotid arteries, renal arteries, *etc.* Restenosis generally results from neointimal hyperplasia. The term "neointimal hyperplasia" refers to the development of a proliferative lesion in the intimal layer of a blood vessel. Neointimal hyperplasia results, for example, from migration of smooth muscle cells of the tunica media layer of the blood vessel toward the lumen into the subintimal space below the endothelium (*i.e.*, the inner lining of the blood vessel). These smooth muscle cells proliferate within the intimal space and create a "mass effect" that narrows the vessel lumen and reduces oxygenation and nutritive blood flow.

20 The term "mRNA" as used herein refers to mature, processed mRNA or to unprocessed, nuclear pre-mRNA transcribed from a gene sequence.

25 The term "liposome" as used herein refers to a lipid-containing vesicle having a lipid bilayer as well as other lipid carrier particles which can entrap antisense oligonucleotides. Liposomes may be made of one or more phospholipids, optionally including other materials such as sterols. Suitable phospholipids include phosphatidyl



cholines, phosphatidyl serines, and many others that are well known in the art. Liposomes can be unilamellar, multilamellar or have an undefined lamellar structure.

The terms "entrap" and "incorporate" when made in reference to an oligonucleotide in a liposome are used herein to mean that the oligonucleotide is at least partially contained somewhere within the wall of the liposome. Thus, an oligonucleotide entrapped in a liposome refers to the presence of the oligonucleotide either partially or completely within the lipid vesicle or within a wall of the lipid vesicle. The molar ratio of lipids in the liposome to the oligonucleotide entrapped in the liposome is preferably between about 100:1 and about 10,000:1, more preferably between about 500:1 and about 5,000:1, and most preferably about 1,000:1.

As used herein, the term "therapeutic amount" refers to that amount of a compound required to reduce, delay, or eliminate undesirable pathologic effects in a subject. A "therapeutic amount" of a compound when made in reference to restenosis refers to that amount of the compound which would diminish restenosis.

The term to "diminish restenosis" as used herein in reference to the effect of a particular composition or of a particular method is meant to reduce, delay, or eliminate restenosis as compared to the level of restenosis observed in the absence of treatment with the particular composition or method. As used herein, the term "reducing" restenosis refers to decreasing the intimal thickening that results from stimulation of smooth muscle cell proliferation. The term "delaying" restenosis refers to increasing the time period between removal of a stenosis (e.g., by use of surgical procedures) and onset of visible intimal hyperplasia (e.g., observed histologically or by angiographic examination). The term "eliminating" restenosis refers to completely "reducing" intimal thickening and/or completely "delaying" intimal hyperplasia in a subject to an extent which makes it no longer necessary to surgically intervene in order to re-establish a suitable blood flow through the vessel by surgical means (e.g., by repeating angioplasty, atherectomy, or coronary artery bypass surgery). The effects of diminishing restenosis in a human subject may be determined by methods routine to those skilled in the art including, but not limited to, angiography, ultrasonic evaluation, fluoroscopic imaging, fiber optic endoscopic examination or biopsy and histology.

The effects of diminishing restenosis in a non-human animal subject may be determined by, for example, methods described herein including a reduction in the intimal/media cross-sectional ratio as measured by light microscopy of formalin-fixed tissue.

5           The term "substantially free of restenosis" when used in reference to a tissue of a subject refers to a subject in which clinical symptoms of restenosis in the tissue are substantially absent. Methods for determining substantial absence of clinical symptoms are known in the art. For example, the substantial absence of restenosis in coronary arterial vessels may be determined, for example, by cardiac catheterization and  
10       coronary angiograms which are capable of revealing the absence or presence of restenotic lesions, as well as by a thallium stress test which is capable of determining coronary blood flow that is indicative of occlusion by restenotic lesions.

          The term to "diminish osteopontin expression" as used herein in reference to the effect of a particular composition or of a particular method on a tissue is meant to  
15       reduce the level of osteopontin expression in that tissue to a quantity which is less than the quantity of osteopontin expression in a corresponding control tissue which is, for example, not treated with that composition or method. For example, in order to determine whether a composition diminishes osteopontin expression in arterial  
20       atherectomy tissue from a subject, an arterial atherectomy tissue sample is removed from the subject, treated in the presence or absence of the composition, and the level of osteopontin expression measured in the arterial atherectomy tissue which had been treated in the presence or absence of the composition. The detection of a level of  
25       osteopontin expression in the arterial atherectomy tissue which had been treated with the composition that is lower than the level of osteopontin expression in the arterial atherectomy tissue which had not been treated with the composition demonstrates that  
30       the composition diminishes osteopontin expression.

          The term "higher levels of plasma osteopontin" when made in reference to a first subject suspected of being capable of developing restenosis in a tissue refers to a quantity of plasma osteopontin in the first subject which is greater than the quantity of  
30       plasma osteopontin in a second subject substantially free of restenosis in that tissue,

preferably at least twice as great as, more preferably at least five times as great as, and most preferably at least ten times as great as the quantity in the second subject as determined by, for example, Western blot analysis of osteopontin and immunofluorescence for detection of osteopontin as described herein.

5           The term "antisense" as used herein refers to a deoxyribonucleotide sequence whose sequence of deoxyribonucleotide residues is in reverse 5' to 3' orientation in relation to the sequence of deoxyribonucleotide residues in a sense strand of a DNA duplex. A "sense strand" of a DNA duplex refers to a strand in a DNA duplex which is transcribed by a cell in its natural state into a "sense mRNA." Sense mRNA  
10           generally is ultimately translated into a polypeptide. Thus an "antisense" sequence is a sequence having the same sequence as the non-coding strand in a DNA duplex. The term "antisense mRNA" refers to a ribonucleotide sequence whose sequence is complementary to an "antisense" sequence.

          The term "oligonucleotide analog" as used herein refers to an oligonucleotide  
15           which comprises non-naturally-occurring portions. Thus, an oligonucleotide analog may have one or more altered sugar moieties, inter-sugar linkages, or altered base units. Altered inter-sugar linkages include, for example, substitution of the phosphodiester bonds of the oligonucleotide with sulfur-containing bonds, phosphorothioate bonds, alkyl phosphorothioate bonds, N-alkyl phosphoramidates,  
20           phosphorodithioates, alkyl phosphonates and short chain alkyl or cycloalkyl structures.

          The term "portion" when used in reference to a nucleotide sequence refers to fragments of that nucleotide sequence. The fragments may range in size from 5 nucleotide residues to the entire nucleotide sequence minus one nucleic acid residue.

          As used herein, the terms "vector" and "vehicle" are used interchangeably in  
25           reference to nucleic acid molecules that transfer DNA segment(s) from one cell to another.

          The term "expression vector" or "expression cassette" as used herein refers to a recombinant DNA molecule containing a desired coding sequence and appropriate nucleic acid sequences necessary for the expression of the operably linked coding  
30           sequence in a particular host organism. Nucleic acid sequences necessary for

expression in prokaryotes usually include a promoter, an operator (optional), and a ribosome binding site, often along with other sequences. Eukaryotic cells are known to utilize promoters, enhancers, and termination and polyadenylation signals.

The terms "in operable combination", "in operable order" and "operably linked" as used herein refer to the linkage of nucleic acid sequences in such a manner that a nucleic acid molecule capable of directing the transcription of a given gene and/or the synthesis of a desired protein molecule is produced. The term also refers to the linkage of amino acid sequences in such a manner so that a functional protein is produced.

The term "recombinant protein" or "recombinant polypeptide" as used herein refers to a protein molecule which is expressed using a recombinant DNA molecule.

As used herein, the terms "complementary" or "complementarity" when used in reference to polynucleotides refer to polynucleotides which are related by the base-pairing rules. For example, the sequence 5'-AGT-3' is complementary to the sequence 5'-ACT-3'. Complementarity may be "partial," in which one or more nucleic acid bases in one strand is not matched according to the base pairing rules with a nucleic acid base in another strand. Or, there may be "complete" or "total" complementarity between the nucleic acids. The degree of complementarity between nucleic acid strands has significant effects on the efficiency and strength of hybridization between nucleic acid strands. This is of particular importance in methods which depend upon binding between nucleic acids.

The term "homology" when used in relation to nucleic acids refers to a degree of complementarity. There may be partial homology or complete homology (*i.e.*, identity). A partially complementary sequence is one that at least partially inhibits a completely complementary sequence from hybridizing to a target nucleic acid is referred to using the functional term "substantially homologous." The inhibition of hybridization of the completely complementary sequence to the target sequence may be examined using a hybridization assay (Southern or Northern blot, solution hybridization and the like) under conditions of low stringency. A substantially homologous sequence or probe (*i.e.*, an oligonucleotide which is capable of hybridizing

to another oligonucleotide of interest) will compete for and inhibit the binding (*i.e.*, the hybridization) of a completely homologous sequence to a target under conditions of low stringency. This is not to say that conditions of low stringency are such that non-specific binding is permitted; low stringency conditions require that the binding of two sequences to one another be a specific (*i.e.*, selective) interaction. The absence of non-specific binding may be tested by the use of a second target which lacks even a partial degree of complementarity (*e.g.*, less than about 30% identity); in the absence of non-specific binding the probe will not hybridize to the second non-complementary target.

Low stringency conditions when used in reference to nucleic acid hybridization comprise conditions equivalent to binding or hybridization at 42°C in a solution consisting of 5X SSPE (43.8 g/l NaCl, 6.9 g/l NaH<sub>2</sub>PO<sub>4</sub>•H<sub>2</sub>O and 1.85 g/l EDTA, pH adjusted to 7.4 with NaOH), 0.1% SDS, 5X Denhardt's reagent [50X Denhardt's contains per 500 ml: 5 g Ficoll (Type 400, Pharmacia), 5 g BSA (Fraction V; Sigma)] and 100 µg/ml denatured salmon sperm DNA followed by washing in a solution comprising 5X SSPE, 0.1% SDS at 42°C when a probe of about 500 nucleotides in length is employed.

High stringency conditions when used in reference to nucleic acid hybridization comprise conditions equivalent to binding or hybridization at 42°C in a solution consisting of 5X SSPE (43.8 g/l NaCl, 6.9 g/l NaH<sub>2</sub>PO<sub>4</sub>•H<sub>2</sub>O and 1.85 g/l EDTA, pH adjusted to 7.4 with NaOH), 0.5% SDS, 5X Denhardt's reagent and 100 µg/ml denatured salmon sperm DNA followed by washing in a solution comprising 0.1X SSPE, 1.0% SDS at 42°C when a probe of about 500 nucleotides in length is employed.

When used in reference to nucleic acid hybridization the art knows well that numerous equivalent conditions may be employed to comprise either low or high stringency conditions; factors such as the length and nature (DNA, RNA, base composition) of the probe and nature of the target (DNA, RNA, base composition, present in solution or immobilized, etc.) and the concentration of the salts and other components (*e.g.*, the presence or absence of formamide, dextran sulfate, polyethylene glycol) are considered and the hybridization solution may be varied to generate

conditions of either low or high stringency hybridization different from, but equivalent to, the above listed conditions.

The term "hybridization" as used herein includes "any process by which a strand of nucleic acid joins with a complementary strand through base pairing."

5 [Coombs J (1994) *Dictionary of Biotechnology*, Stockton Press, New York NY].

The terms "hybridizable" and "capable of hybridizing" refer to the ability of one strand of nucleic acid to join with a completely or partially complementary strand via base pairing under high or low stringency conditions.

10 As used herein the term "stringency" is used in reference to the conditions of temperature, ionic strength, and the presence of other compounds such as organic solvents, under which nucleic acid hybridizations are conducted. "Stringency" typically occurs in a range from about  $T_m$  to about 20°C to 25°C below  $T_m$ . As will be understood by those of skill in the art, a stringent hybridization can be used to identify or detect identical polynucleotide sequences or to identify or detect similar or  
15 related polynucleotide sequences. Under "stringent conditions" SEQ ID NO:15 or fragments thereof will hybridize to its exact complement and closely related sequences.

The term "atherosclerosis" refers to a form of arteriosclerosis in which deposits of yellowish plaques (*i.e.*, atheromas) containing cholesterol, lipid material, and lipophages are formed within the intima and inner media of large and medium-sized  
20 arteries.

The term "angioplasty" refers to surgery of blood vessels as exemplified by percutaneous transluminal coronary angioplasty (PTCA), wherein a balloon in a catheter is inflated to open the lumen of an artery blocked by atherosclerotic plaques to allow blood flow, and by directional coronary atherectomy (DCA), wherein an  
25 atherosclerotic plaque is removed from the lumen of a blocked artery.

## DESCRIPTION OF THE INVENTION

The present invention provides sequences capable of inhibiting osteopontin (OPN) expression. More particularly, the sequences provided herein are antisense OPN sequences. Also provided by the invention are methods for treating restenosis.

The compositions and methods provided by this invention are useful in treating restenosis associated with traumatic injury to vascular walls. In particular, the compositions and methods provided herein are useful for treating restenosis following vascular surgery, e.g., percutaneous transluminal coronary angioplasty (PCTA), directional coronary atherectomy (DCA), and the like. Moreover, the compositions described herein find utility in inhibiting osteopontin expression *in vitro* and in *in vivo* animal model systems.

To facilitate understanding of the inventions provided herein, the description of the invention is divided into (a) antisense osteopontin, and (b) methods for treating restenosis.

#### A. Antisense Osteopontin Sequences

Osteopontin was first identified in 1979 (Senger *et al.* (1979) Cell 16:885-893) as a transformation-related phosphoprotein and was later named osteopontin (OPN) (Franzen *et al.* (1985) Biochem. J. 232:715-724). It is a secreted non-collagenous, glycosylated phosphoprotein (Oldberg *et al.* (1988) J. Biol. Chem. 263:19433-19436; Nemir *et al.* (1989) J. Biol. Chem. 264:18202-18208; Craig *et al.* (1989) Int. J. Cancer 46:133-137; Denhardt *et al.* (1993) FASEB J. 7:1475-1482) which binds to cell surface integrins (Hynes (1992) Cell 69:11-25), a family of hetero-dimeric glycoprotein subunits designated  $\alpha$  and  $\beta$ . These integrins act as cell surface receptors for many ligands, including OPN (Oldberg *et al.* (1986) Proc. Natl. Acad. Sci. USA. 83:8819-8823). OPN gene expression has been reported to be a distinctive feature of rat aortic smooth muscle cells (Giachelli *et al.* (1991) Biochem. Biophys. Res. Commun. 177:867-873). Moreover, rat and bovine smooth muscle cell (SMC)-migration is promoted by OPN (Liaw *et al.* (1994) Circ. Res. 74:214-224). It has also been demonstrated that high levels of OPN-mRNA and protein are detectable in the rat and human aorta, and carotid arteries during neointima formation (Ikeda *et al.* (1993) J. Clin. Invest. 92:2814-2820; Giachelli *et al.* (1993) J. Clin. Invest. 92:1686-1696; Shanahan *et al.* (1994) J. Clin. Invest. 93:2393-2402; Liaw *et al.* (1995) J. Clin.

Invest. 95:713-724). OPN overexpression has been shown to associate with rat arterial SMC proliferation (Gadeau *et al.* (1993) *Arteriosclerosis & Thrombosis* 13:120-125), and its levels have been reported to increase in atherosclerotic plaques and during restenosis which follows balloon angioplasty (*see*, Rodan (1994) "Osteopontin overview," In "Annals New York Acad. Sci." pp 1-5). Most interestingly, it has been demonstrated that subjecting cultured cells to intermittent compressive force, similar to the forces which may be produced by some angioplasty procedures, causes OPN overexpression (Kubota *et al.* (1993) *Archs. Oral Biol.* 38:23-30).

Without intending to limit the invention to a particular theory, data presented herein suggest that one mechanism which contributes to restenosis is the migration of coronary artery smooth muscle cells (CASMCs) to the site of injury caused by angioplasty and subsequent proliferation of migrated CASMCs.

Also without limiting the invention to any particular theory or mechanism, data from *in vitro* and *in vivo* investigations presented herein suggest that there may be a cascade of events which lead to the development of restenosis after angioplasty and that OPN plays both autocrine and paracrine receptor-mediated roles which critically affect the biology of coronary artery smooth muscle cells (CASMCs). OPN has been reported to have chemotactic properties (Liaw *et al.* (1994) *Circ. Res.* 74:214-224) and has been demonstrated to induce proliferation in rat aortic smooth muscle cells (SMCs) (Gadeau *et al.* (1993) *Arteriosclerosis & Thrombosis* 13:120-125). Thus, a likely scenario is that the inflammatory stimulus generated by the trauma of angioplasty is the triggering event which causes infiltration of monocytes and macrophages into the vascular smooth muscle layer. Since activated monocytes and macrophages are known to secrete OPN, the secreted OPN may bind to  $\alpha_v\beta_3$  integrin on CASMCs, which may in turn respond by expressing yet more OPN. Secreted OPN then interacts with CASMCs in an autocrine or paracrine fashion and promotes their migration towards the intima where the angioplasty-induced injury has occurred. These cells then invade the ECM and finally, proliferate to cause reocclusion.



It has been reported that vascular smooth muscle cells, when stimulated with vitronectin, undergo haptotaxis (Naito *et al.* (1991) Exp. Cell Res. 194:154-156), a process in which the cells migrate towards an increasing gradient of a chemoattractant. More recently, Senger *et al.* (Senger *et al.* (1996) Am. J. Pathol. 149:293-305) have demonstrated that OPN and its GRGDS-containing thrombin cleavage fragment promote tumor and vascular endothelial cell haptotaxis respectively, via the  $\alpha_v\beta_3$  integrin. Data presented herein demonstrate that plasma OPN levels dramatically increase following treatment of patients with the DCA procedure. This increase may create an increasing gradient of this protein from the media of the arterial wall (where the CASMCs are normally located) to the lumen of the artery, where the highest concentration of OPN may be found. This data, combined with further results provided herein, which demonstrate the ability of CASMCs to migrate towards a higher concentration of OPN, to invade ECM, and to proliferate in response to OPN may explain the role of OPN in arterial occlusion (*i.e.*, restenosis) following DCA procedure. Without intending to limit the invention to any theory, it is hypothesized that the establishment of such an OPN gradient *in vivo* results in the migration of CASMCs from their original location in the arterial media, invasion of the arterial ECM, and arrival at their destination in the intima. It is further hypothesized that CASMCs arriving at the intima proliferate in response to OPN-stimulation, thus resulting in reocclusion.

While there may be other factors involved in the pathogenesis of this disease process, results presented herein demonstrates that OPN and its  $\alpha_v\beta_3$  integrin receptor play an essential role not only in stimulating the migration and ECM-invasion but also of proliferation of CASMCs.

Importantly, data presented herein which demonstrate for the first time that lipofection of CASMCs with OPN-antisense phosphorothioate-oligonucleotides results in a drastic inhibition of CASMC proliferation has far reaching clinical significance, *i.e.*, that reocclusion of vessels following vascular trauma may be diminished by administration of OPN-antisense oligonucleotide sequences.

The present invention provides antisense OPN sequences. In one embodiment, the antisense OPN sequence of the invention is SEQ ID NO:9. In another embodiment, the antisense OPN sequence provided herein is SEQ ID NO:10. In yet another embodiment, the antisense OPN sequence disclosed by the present invention is  
5 SEQ ID NO:11. In a further embodiment, the antisense OPN sequence is SEQ ID NO:12. In yet a further embodiment, the antisense OPN sequence of the invention in SEQ ID NO:13.

The antisense OPN sequences of the invention are not limited to the antisense OPN sequences provided herein. Any antisense sequence is contemplated to be within  
10 the scope of this invention if it is capable of reducing the level of expression of OPN to a quantity which is less than the quantity of OPN expression in a corresponding control tissue which is (a) not treated with the antisense OPN sequence, (b) treated with a corresponding sense OPN sequence, or (c) treated with a nonsense sequence. The terms "reducing the level of expression of OPN," "diminishing osteopontin  
15 expression" and grammatical equivalents thereof refer to reducing the level of OPN expression to a quantity which is preferably 30% less than the quantity in a corresponding control tissue, more preferably 90% less than the quantity in a corresponding control tissue, and most preferably is at the background level of, or is undetectable by, a Western blot analysis of OPN, immunofluorescence for detection of  
20 OPN, reverse transcription polymerase chain (RT-PCR) reaction for detection of OPN mRNA, or by *in situ* hybridization for detection of OPN mRNA as described herein. When a background level or undetectable level of OPN or of OPN mRNA is measured, this may indicate that OPN is not expressed, and thus that OPN is ineffective. A reduced level of OPN need not, although it may, mean an absolute  
25 absence of expression of OPN. The invention does not require, and is not limited to, antisense OPN sequences which eliminate expression of OPN.

Antisense osteopontin sequences capable of reducing the level of osteopontin expression include, for example, sequences which are capable of hybridizing with at least a portion of SEQ ID NO:15 under high stringency or low stringency conditions  
30 as described herein.

## 1. Design

Antisense OPN sequences within the scope of this invention may be designed using approaches known in the art. In a preferred embodiment, the antisense OPN sequences are designed to be hybridizable to OPN mRNA encoded by the coding region of the OPN gene as shown in Figure 5, (SEQ ID NO:15) (Kiefer et al. (1989) Nucleic Acids Res. 17:3306). Antisense OPN sequences which are designed to hybridize to OPN mRNA which is encoded by the OPN gene coding region interfere with the normal function of the mRNA, e.g., translocation to the situs for protein translation, binding to ribosomes, *etc.*, thus resulting in reduced translation of OPN mRNA.

Alternatively, antisense OPN sequences may be designed to reduce transcription by hybridizing to upstream nontranslated sequences, thereby preventing promoter binding to transcription factors.

In a preferred embodiment, the antisense oligonucleotide sequences of the invention range in size from about 8 to about 100 nucleotide residues. In yet a more preferred embodiment, the oligonucleotide sequences range in size from about 8 to about 30 nucleotide residues. In a most preferred embodiment, the antisense OPN sequences have 20 nucleotide residues.

However, the invention is not intended to be limited to the number of nucleotide residues in the oligonucleotide sequence disclosed herein. Any oligonucleotide sequence which is capable of reducing expression of OPN is contemplated to be within the scope of this invention. For example, oligonucleotide sequences may range in size from about 3 nucleotide residues to the entire OPN cDNA sequence of Figure 5. The art skilled know that the degree of sequence uniqueness decreases with decreasing length, thereby reducing the specificity of the oligonucleotide for the OPN mRNA.

In a preferred embodiment, the antisense oligonucleotide sequences of the invention comprise an oligonucleotide analog. In yet a more preferred embodiment, the oligonucleotide analog contains one or more phosphorothioate bonds.

However, the antisense oligonucleotides of the invention are not limited to oligonucleotide analogs with phosphorothioate linkages. The invention is contemplated to include within its scope any oligonucleotide sequences so long as it is capable of hybridizing under low stringency or high stringency conditions to the target human OPN mRNA. Oligonucleotides which hybridize under high stringency conditions to the target human OPN mRNA are preferred since such oligonucleotides exhibit high specificity for the human OPN mRNA. Oligonucleotides which are contemplated to be within the scope of this invention include, for example, the antisense oligonucleotide sequences of the invention may comprise naturally occurring nucleotide residues as well as nucleotide analogs. Nucleotide analogs may include, for example, nucleotide residues which contain altered sugar moieties, altered inter-sugar linkages (e.g., substitution of the phosphodiester bonds of the oligonucleotide with sulfur-containing bonds, phosphorothioate bonds, alkyl phosphorothioate bonds, N-alkyl phosphoramidates, phosphorodithioates, alkyl phosphonates and short chain alkyl or cycloalkyl structures), or altered base units. Oligonucleotide analogs are desirable, for example, to increase the stability of the antisense oligonucleotide compositions under biologic conditions since natural phosphodiester bonds are not resistant to nuclease hydrolysis. Oligonucleotide analogs may also be desirable to improve incorporation efficiency of the oligonucleotides into liposomes, to enhance the ability of the compositions to penetrate into the cells where the nucleic acid sequence whose activity is to be modulated is located, in order to reduce the amount of antisense oligonucleotide needed for a therapeutic effect thereby also reducing the cost and possible side effects of treatment.

## 2. Synthesis

Antisense OPN oligonucleotide sequences may be synthesized using any of a number of methods known in the art, as well as using commercially available services (e.g., Genta, Inc.). Synthesis of antisense oligonucleotides may be performed, for example, using a solid support and commercially available DNA synthesizers. Alternatively, antisense oligonucleotides may also be synthesized using standard

phosphoramidate chemistry techniques. For example, it is known in the art that for the generation of phosphodiester linkages, the oxidation is mediated via iodine, while for the synthesis of phosphorothioates, the oxidation is mediated with 3H-1,2-benzodithiole-3-one,1,-dioxide in acetonitrile for the step-wise thioation of the phosphite linkages. The thioation step is followed by a capping step, cleavage from the solid support, and purification on HPLC, e.g., on a PRP-1 column and gradient of acetonitrile in triethylammonium acetate, pH 7.0.

### C. Methods for Treating Restenosis

The present invention provides methods for the treatment of restenosis. In one embodiment, the methods of the invention comprise administering a therapeutic amount of an OPN antisense oligonucleotide to a subject under conditions such that restenosis symptoms are diminished. In a preferred embodiment, the restenosis sought to be alleviated by the methods of the invention is that which may follow vascular trauma from vascular surgical procedures such as angioplasty. Angioplasty may be performed, for example, by percutaneous trans-luminal coronary angioplasty (PTCA) or by directional coronary atherectomy (DCA). PTCA generally involves inserting a catheter (*i.e.*, a plastic tube) with a balloon on the end into the blood vessel and inflating the balloon to high pressures to dilate the lumen of a blood vessel that is narrowed e.g. by atherosclerosis (*i.e.*, hardening of the artery). DCA involves inserting a catheter with a probe at the end (the probe is generally metallic in order to permit X-ray visualization during the surgical procedure) into the blood vessel and removing atherosclerotic tissue from the lumen of the vessel with the probe.

However, the methods of the invention are not limited to vascular trauma from angioplastic procedures. Any procedure which results in restenosis is contemplated to be within the scope of the invention. Such procedures include, for example, atheroectomy, placement of a stent (e.g., in a vessel), thrombectomy, and grafting. Atheroectomy may be performed, for example, by surgical excision, ultrasound or laser treatment, or by high pressure fluid flow. Introduction of a stent generally involves introducing a wire-mesh cylinder within the lumen of a stenotic vessel to

increase the lumen diameter and restore blood flow. Thrombectomy may be performed by, for example, introducing into the vessel a pneumatically operated catheter which is fitted with rotating blades at the tip to remove the thrombus or clot. Grafting may be achieved, for example, by vascular grafting using natural or synthetic materials, or by surgical anastomosis of vessels such as during organ grafting.

### 1. Delivery

In a preferred embodiment, the antisense sequences provided herein are delivered as liposomal oligonucleotides. In a more preferred embodiment, the liposomal composition used to entrap the antisense oligonucleotide sequences of the invention is "LIPOFECTIN." "LIPOFECTIN" is a 1:1 (w/w) formulation of the cationic lipid N-[1-(2, 3-dioleoyloxy)propyl]-N,N,N-trimethylammonium chloride (DOTMA) and dioleoyl phosphatidylethanolamine (DOPE). The positively charged and neutral lipids from liposomes that can complex with nucleic acids. Successful direct physical transfer of genes into intact blood vessels *in vivo* using cationic liposomes (*e.g.*, "LIPOFECTIN") has been reported [Nabel et al. (1990) Science 244:1285-1288]. Nabel et al. reported that after initial incubation with the liposomes using a double-balloon catheter, expression of the transfected DNA could be detected in the vessel wall for up to five months. Lim et al. [Lim et al. (1991) Circulation 83:2007-2011] have also reported successful cationic-lipid-mediated gene transfer into intact canine coronary and peripheral arteries. Successful lipofection of circulatory vessels has also been reported by Lynch et al. [Lynch et al. (1992) Proc. Natl. Acad. Sci. USA 89:1138-1142] and Flugelman et al. [Flugelman et al. (1992) Circulation 85:1110-1117].

The invention is not limited to the type or composition of the liposome. Any liposome which may be deemed useful by one of skill in the art for use with the antisense molecules of the invention is contemplated to be within the scope of this invention. Liposomes of different compositions are known in the art and are exemplified by those described herein or those known in the art [*e.g.*, U.S. Patent No. 5,417,978 the contents of which are herein incorporated by reference].

Delivery of the antisense oligonucleotides of the invention is not limited to the use of liposomal oligonucleotides. The antisense oligonucleotides provided herein may be delivered to a target cell in various forms including, but not limited to, as free oligonucleotides or as oligonucleotides complexed with other compositions.

5           Where the antisense oligonucleotides of the invention are complexed with other compositions, such as with a combination of liposomes and the protein coat of the inactivated hemagglutinating virus of Japan (HVJ) [Morishita et al. (1993) Proc. Natl. Acad. Sci. USA 90:8474-8478], or with a combination of liposomes, inactivated HVJ coat protein and nuclear protein [Kaneda et al. (1989) Science 243:375-378; von der  
10   Leyen et al. (1994) FASEB J. 8:A802]. Antisense oligonucleotides complexed with liposomes and the protein coat of HVJ have been shown to result in a more rapid cellular uptake and a 10-fold higher transfection efficiency of antisense oligonucleotides or plasmid DNA than lipofection or passive uptake methods [Morishita et al. (1993) J. Clin. Invest. 91:2580-2585]. In an alternative embodiment,  
15   antisense oligonucleotide sequences may be administered in pluronic gels (BASF Wyandotte Corp., Wyandotte, MI).

Transfer of antisense sequences into vascular smooth muscle cells may be accomplished by other methods known in the art, including re-implantation of cells modified *in vitro* [for a review, see, Dzau et al. (1993) Trends Biotechnol. 11:205-  
20   210].

Alternatively, antisense sequences may be introduced into a cell by transferring into the target cell a vector capable of expression of the antisense sequence. In particular, viral-vector mediated gene transfer is known in the art such as such as retrovirus, adenovirus, Hemagglutinating virus of Japan (HVJ; also referred to as  
25   Sendai virus). Vectors which express antisense OPN oligonucleotide sequences can flood cells with untranslatable antisense mRNA sequences which inhibit expression of OPN either by inhibiting transcription of the OPN gene or inhibiting translation of an OPN-encoding mRNA. For example, vectors derived from oncoretroviruses, such as the Moloney leukemia virus (MLV), integrate the transgene in the genome of the  
30   target cells without transferring any viral gene, two properties considered crucial for

the sustained expression of the transgene. These retroviral vectors may be particularly suitable for targeting OPN gene expression in proliferating human smooth muscle cells since these vectors only transduce cells that divide shortly after infection [Miller et al. (1990) Mol. Cell. Biol. 10:4239-4242], and do not transduce non-dividing cells

5 [Naldini et al. (1996) Science 272:263-267].

Other virus-derived vectors which are suitable for *in vivo* gene transfer are available in the art including human immunodeficiency virus-derived vectors [Naldini et al. (1996) Science 272:263-267; Naldini et al. (1996) Proc. Natl. Acad. Sci. USA 93:11382-11388], adenovirus-derived vectors [Lemarchand et al. (1993) Circ. Res.

10 72:1132-1138], retroviruses such as BAG and BAL [Wilson et al. (1989) Science 244:1344-1346]. While adenovirus-derived vectors are available, and their expression is temporary (*i.e.*, making them suitable for treatment of acute disease such as restenosis following angioplastic surgery) these vectors are not preferred since an immune response is raised *in vivo* against the transduced cells thus resulting in

15 inflammation which would exacerbate the risk of restenosis. Similarly, while vectors derived from retroviruses (*e.g.*, human immunodeficiency virus) are available, their use is not preferred as these vectors are expressed only in non-dividing cells, and would therefore be expected not to transduce proliferating smooth muscle cells during restenosis.

20 Methods for the design of a viral vector are known in the art. Generally, the design of a viral vector system relies upon the segregation in the viral genome of *cis*-acting sequences involved in its transfer to target cells from *trans*-acting sequences encoding the viral proteins. The prototype vector particle is assembled by viral proteins which are expressed from constructs stripped of all *cis*-acting sequences.

25 These sequences are instead used to frame the expression cassette for the transgene driven by an heterologous promoter. As the particle will transfer only the latter construct, the infection process is limited to a single round without spreading. The safety and efficiency of an actual vector system depends on the extent to which complete segregation of *cis*- and *trans*-acting functions is obtained.



## 2. Dosage

Those skilled in the art will recognize that the appropriate therapeutic dosage of the oligonucleotides of the invention for a given vascular surgical procedure may be determined in *in vitro* and *in vivo* animal model systems, and in human preclinical trials. *in vitro* testing may be accomplished using commercially available human coronary artery smooth muscle cells (CASMCs) coupled with determination of the effect of antisense oligonucleotide treatment on OPN expression as measured by Western blot analysis, cellular proliferation and migration, and on extracellular matrix invasion, as described herein. *In vivo* testing of a suitable therapeutic dose may be accomplished using art-accepted animal models such as the rat carotid artery model described herein, in which the effect of antisense oligonucleotide treatment on OPN expression, DNA synthesis and intimal/medial cross-sectional ratios are determined.

Generally, where the antisense oligonucleotides of the invention are delivered as liposomal oligonucleotides, the dose of the antisense oligonucleotide ranges preferably between about 1  $\mu$ M and about 500  $\mu$ M, more preferably between about 1  $\mu$ M and about 100  $\mu$ M, and most preferably between about 5  $\mu$ M and about 15  $\mu$ M.

## 3. Delivery Routes

In a preferred embodiment, the antisense oligonucleotides of the present invention are administered locally to the site of vascular trauma by using an infusion catheter. Infusion catheters are commercially available (*e.g.*, C.R. Bard Inc., Billerica, Mass.) and known in the art (*e.g.*, infusion catheters described by Wolinsky in U.S. Patent No. 4,824,436, or by Spears in U.S. Patent No. 4,512,762, the contents of both patents are herein incorporated by reference). The infusion catheter may be conveniently a double balloon or quadruple balloon catheter with a permeable membrane.

The invention is not limited to local delivery by catheter. The antisense oligonucleotides of the invention may be delivered to the smooth muscle layers of a mammalian artery wall by a number of routes such as, for example, the biodegradable

materials exemplified by those described in U.S. Patent No. 4,929,602 (the contents of which are incorporated by reference) which are impregnated with the sequences of the invention.

5 Alternatively, local delivery of the antisense nucleotides of the invention may be achieved by using, for example, implanted osmotic pumps, or by inclusion of the oligonucleotide sequences into pluronic gels such as those available from BASF Wyandotte Corp., Wyandotte, MI. One of skill in the art would appreciate that the antisense sequences of the present invention may need only to be delivered in a therapeutic dosage sufficient to expose the proximal (*i.e.*, 6 to 9) cell layers of the  
10 intimal or tunica media cells which line the lumen of a blood vessel. Such a dosage can be determined empirically by, for example, infusing vessels from suitable animal model systems and using immunohistochemical methods to detect the presence and cellular localization of OPN protein. Alternatively, dosage may also be empirically determined by conducting suitable *in vitro* investigation as described herein.

15 It is further preferred, though not required, that the use of an infusion catheter to administer the antisense sequences of the invention be performed substantially contemporaneously (*i.e.*, during the same surgical procedure which is employed to alleviate stenosis) with the performance of the surgical procedures which result in vascular trauma. Such contemporaneity is desirable since it (a) is convenient, (b)  
20 avoids unnecessary further trauma to the blood vessels which otherwise would result from independent catheter infusion and angioplasty procedures, and (c) provides a greater probability of preventing restenosis since significant elevation of the levels of circulating OPN occur as early as 24 hours within performance of an angioplastic procedure as disclosed by this invention, and since approximately 30-50% of the  
25 patients undergoing angioplastic procedures suffer from restenosis within 3 days to 3 months.

One of skill in the art would recognize that a suitable therapeutic dosages of antisense oligonucleotides administered *in vivo* by a catheter is dependent on several factors including, but not limited to, a) the atmospheric pressure applied during  
30 infusion; b) the time over which the composition administered resides at the vascular

site; c) the nature of the employed composition which contains the oligonucleotides of the invention; and/or d) the nature of the vascular trauma and therapy desired. Those skilled in the art will recognize that infiltration of compositions containing antisense oligonucleotide sequences into the smooth muscle layers of a mammalian artery wall will probably be variable and will need to be determined on an individual basis. Such determination is routine, and follows similar principles as those known to and applied by practitioners in the art in using a multitude of drugs which are administered routinely.

While infusion catheters are contemplated to provide a preferred administration route, one of skill in the art would recognize that other methods for delivery or routes of administration may also be useful, *e.g.*, injection by the intravenous, intralymphatic, intrathecal, intraarterial, or other intracavity routes. These routes are not preferred since attaining a therapeutic level at the site of potential restenosis would require administration of a large amount of oligonucleotide sequence which is costly

One of skill in the art knows that the sequences of the invention may be administered using a number of pharmaceutically acceptable carriers (*i.e.*, excipients). In a preferred embodiment, the pharmaceutically acceptable carrier is in liquid phase. Useful pharmaceutically acceptable carriers include generally employed carriers, such as phosphate buffered saline solution, water, emulsions (*e.g.*, oil/water and water/oil emulsions) and wetting agents of various types.

#### 4. Timing and Number of Doses

It is contemplated that administration of antisense sequences of the present invention may be continuous or intermittent, depending, for example, upon the recipient's physiological condition, whether the purpose of the administration is therapeutic or prophylactic and other factors known to those skilled in the art.

The methods of the invention are not limited to the number or timing of administration of the antisense oligonucleotide sequences provided herein. For example, dosages for the prevention of restenosis following angioplasty, may be applied prior to, simultaneously with, and/or subsequent to the surgical intervention

procedure. In one embodiment of a dosing regimen, a "pre-loading" dose may be administered prior to or at the time of the intervention. A preloading dose may be a single pre-loading dose (*i.e.*, where the oligonucleotides of the invention are administered at a single point in time) or a multiple pre-loading dose (*i.e.*, where the oligonucleotides of the invention are administered at multiple points in time). For example, a single pre-loading dose may be administered about 24 hours prior to intervention, while multiple pre-loading doses may be administered daily for several days prior to intervention. In another embodiment of a dosing regimen, a "contemporaneous dose" may be administered, *i.e.* where the oligonucleotides of the invention are administered during the surgical intervention procedure. In yet another embodiment of a dosing regimen, a "follow up" dose may be delivered subsequent to the intervention surgical procedure. An example of a follow up dose is a daily administration one to two weeks or longer following intervention. One of skill in the art would appreciate that the dosing regimen is selected so as to minimize the proliferative effect of osteopontin following surgical intervention for a time sufficient to substantially reduce the risk of, or to prevent, restenosis. One of skill in the art also knows that the dosing regimens may be determined empirically by *in vitro* testing, *in vivo* testing in animal models, and by pre-clinical testing in human subjects. It is preferred, though not required, that a dosing regimen employ a contemporaneous dose.

The methods of the invention are not limited to the duration of administration of the antisense sequences provided herein. Administration may be for a short time (*i.e.*, delivery over a period of time equal to or less than about 2-3 minutes) or chronic (*i.e.*, continued or sporadic delivery which is continued over a period of time greater than 10 minutes). Administration for a short time may be useful to offset, at least partially, the strong stimulus for vascular smooth muscle cell proliferation caused by highly traumatic injuries or procedures such as angioplasty. On the other hand, chronic delivery of a lower dose delivered to the traumatized site may provide further protection against restenosis resulting from vascular smooth muscle cell proliferation in

the traumatized area. In a preferred embodiment, administration is for a short time. More preferably, administration is for about 2-3 minutes.

## EXPERIMENTAL

5 The following examples serve to illustrate certain preferred embodiments and aspects of the present invention and are not to be construed as limiting the scope thereof.

In the experimental disclosure which follows, the following abbreviations apply: CASMC (coronary artery smooth muscle cells); OPN (osteopontin); DCA (directional coronary atherectomy); DSS (disuccinimidyl suberate); PMSF (phenyl  
10 methyl sulfonyl- fluoride); PBS (phosphate buffered saline); PMA (phorbol 12-myristate 13-acetate); RT-PCR (reverse transcription polymerase chain reaction); ECM (extracellular matrix); FCM (fibroblast conditioned medium); American Histolabs (Rockville, MD); BASF Wyandotte Corporation (Wyandotte, MI); Boehringer Mannheim (Indianapolis, IN); Charles Rivers (Michigan, OH); Chemicon (Temecula,  
15 CA); (Collaborative Research, Bedford, MA); Clonetics (San Diego, CA); Costar (Cambridge, MA); ICN (Biomedicals, CA), Pharmacia Biotechnology, Inc. (Piscataway, NJ); Sigma (St. Louis, MO).

### EXAMPLE 1

20 Expression of OPN mRNA and Protein In  
Cultured Human Coronary Artery Smooth Muscle Cells

The pattern of OPN-mRNA and protein expression in proliferating cultured human coronary artery smooth muscle cells (CASMCs) was investigated using reverse transcription polymerase chain reaction (RT-PCR) and Western blot analysis on commercially available CASMCs. CASMCs (Clonetics) were cultured in smooth  
25 muscle cell basal medium (Clonetics) supplemented with insulin (5 µg/ml), human fibroblast growth factor (2 ng/ml), human epidermal growth factor (0.5 ng/ml) and 5% fetal calf serum in a humidified atmosphere of 5% CO<sub>2</sub> and 95% air at 37°C.

Prior to the determination of mRNA and protein expression, immunofluorescence was used in order to determine whether these cells are 100% smooth muscle cells using methods known in the art (Peri *et al.*, (1994) DNA and Cell Biol. 13:495-503). Briefly, CSMCs during log phase of growth on microscopic slides were fixed in 4% buffered paraformaldehyde, embedded in paraffin and histological sections were prepared (American Histolabs). These cell samples were used for immunofluorescent detection of (a) OPN using a previously characterized rabbit OPN-antiserum (Chacklaparampil *et al.*, (1996) Oncogene 12:1457-1467), (b) SMC-specific  $\alpha$ -actin using a monoclonal antibody (clone 1A4) to human SMC-specific  $\alpha$ -actin (Sigma), and (c)  $\alpha_v\beta_3$  integrin using mouse monoclonal antibody to human  $\alpha_v\beta_3$  (Chemicon). These cells expressed each of the three antigens (*i.e.*, OPN, SMC-specific  $\alpha$ -actin, and  $\alpha_v\beta_3$  integrin) thus confirming their smooth muscle cell type.

#### A. Reverse Transcription Polymerase Chain Reaction.

RNA from cultured CSMCs was extracted as previously described (Chomczynski *et al.* (1987) Anal. Biochem. 162:156159). Briefly, the CSMCs were grown in a 75 cm<sup>2</sup> flask, washed in ice-cold PBS three times and lysed in 2 ml of RNA Zol B (Tel-Test, TX). The cell lysates (1 ml each) were transferred to microcentrifuge tubes and 100  $\mu$ l of chloroform were added to each tube. The upper aqueous layers were collected by centrifugation at 12,000 rpm for 15 min. in a clinical centrifuge and the contents (400  $\mu$ l) transferred to another microcentrifuge tube. The RNA samples were precipitated by adding 400  $\mu$ l of isopropanol, collected by centrifugation, washed with 75% cold ethanol and suspended in 15  $\mu$ l DEPC-treated water. The concentration of RNA was measured by a spectrophotometer.

The sequences of the primers and probe used for RT-PCR were derived from the sequence of human OPN cDNA shown in Figure 5. The sequence of the antisense primer, hOPN-R (nt 928-909) was 5'-CTA CAA CCA GCA TAT CTT CA-3' (SEQ ID NO:1) and of the sense primer, hOPN-L (nt 418-437) was 5'-CAC CAG TCT GAT GAG TCT CA-3' (SEQ ID NO:2). The PCR products were detected by using a

digoxigenin-labeled hOPN probe, *i.e.*, hOPN-P<sub>1</sub> (nt 647-628) = 5'-TCC ATG TGT GAG GTG ATG TC-3' (SEQ ID NO:3). Amplification of the cDNA of a control house-keeping gene, *i.e.*, glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was performed using the sense primer, GAPDH-L (nt 388-405) 5'-CCA TGG AGA AGG CTG GGG-3' (SEQ ID NO:4) and the anti-sense primer, GAPDH-R (nt 582-563) 5'-CAA AGT TGT CAT GGA TGA CC-3' (SEQ ID NO:5). The probe, GAPDH-P (nt 549-531) was 5'-CTA AGC AGT TGG TGG TGC A-3' (SEQ ID NO:6).

The results of RT-PCR are shown in Figure 1A. Lane 1 contains CASKCs at log phase of growth; Lane 2 contains CASKCs from confluent cultures. The upper, middle and lower panels are OPN-mRNA, GAPDH mRNA, and OPN protein respectively. During log phase of growth these cells expressed elevated levels of OPN-mRNA (Figure 1A, *panel a: upper lane 1*) compared to the confluent cultures (Figure 1A, *panel a: upper lane 2*). The GAPDH-mRNA signals were identical (Figure 1A, *panel a: middle lanes 1 & 2*) in both non-confluent and confluent cultures, demonstrating that these differences were not due to variability in gel loading or degradation of RNA during extraction.

The data in Figure 1A *panel a* shows that OPN-mRNA and protein were easily detectable when the cells were in log phase of growth while the level was significantly lower when the cells reached confluence.

## B. Western Blot Analysis

The level of OPN in CASKCs was detected by Western blot analysis as previously described (Chackalapampil *et al.*, (1996) *Oncogene* 12:1457-1467). Briefly, the specimens were homogenized in lysis buffer (50 mM Tris-HCl, pH 7.5 containing 150 mM NaCl, 1% Nonidet P40, 15 µg/ml leupeptin and 0.5 µM PMSF), and centrifuged at 12,000 X g for 10 min. The supernatants were electrophoresed on a 4-20% gradient SDS-polyacrylamide gel and electrotransferred to nitrocellulose membrane. The membranes were blocked, incubated with rabbit anti-rat OPN antibody (previously characterized by Chackalapampil *et al.* (Chackalapampil *et al.*, (1996)

Oncogene 12, 1457-1467) (1:250 dilution) and detected with  $^{125}\text{I}$ -protein A (ICN), followed by autoradiography.

The results of the Western blot analysis are shown in Figure 1A *panel a, lower panel*. Western blot analysis of cell extracts showed that high levels of OPN were expressed during the log phase of growth (Fig 1A, *panel a: lower lane 1*), compared to confluent cultures (Fig 1A, *panel a: lower lane 2*).

### C. Immunoprecipitation

An *in vitro* assay was used in order to determine whether an increase in OPN gene expression is detectable. Since phorbol myristate acetate (PMA) is known to induce OPN gene expression, CSMCs were stimulated with PMA, and OPN production was detected by immunoprecipitation of cell lysates followed by Western blotting.

CSMCs were incubated with Phorbol 12-myristate 13-acetate (PMA) (250 nM) at 37°C for 24 h. The cells were immunoprecipitated using a kit [containing 50 mM Tris-HCl (pH 7.5); 150 mM NaCl; 0.5% Na-deoxycholate (detergent mix); protein-A agarose and protease inhibitors (leupeptin, AEBSF, pepstatin and PMSF)] according to manufacturer's (Boehringer Mannheim) instructions. Briefly, the cells were lysed with lysis buffer, centrifuged and the supernatant incubated with rabbit OPN-antibody for 1 h then with protein A-agarose at 4°C overnight. Bound complexes were pelleted by centrifugation, washed and electrophoresed. Western blot analysis was done as described, *supra*. The results are shown in Figure 1A, *panel b*.

In Figure 1A, *panel b*, left lane contains extracts from control cells which were not treated with PMA, while the right lane contains extracts from cells stimulated with 250 nM PMA. The level of OPN protein in PMA-stimulated cells was markedly higher (Figure 1A, *panel b: right lane*) than that of unstimulated cells (Figure 1A, *panel b: left lane*). The two OPN bands (*right lane*) detected upon PMA stimulation represent two isoforms of this protein.



#### D. <sup>125</sup>I-OPN-Binding and Affinity-Crosslinking

Since OPN may exert its effect on CASMCs by interacting with its cell-surface receptor, the amount of membrane bound OPN was determined using <sup>125</sup>I-OPN-binding and affinity-crosslinking experiments.

5 For binding studies, purified hOPN was radioiodinated by the Chloramine-T method (Hunter *et al.*, (1962) Nature 194:495-496). Sub-confluent cultures of CASMCs were incubated with <sup>125</sup>I-OPN (3.3 x 10<sup>5</sup> cpm/well) in the absence or presence of varying concentrations of unlabeled OPN in 0.5 ml Hank's balanced salt solution (HBSS), pH 7.6, containing 0.1% BSA. After incubation at 37°C for 3 h, the  
10 reactions were stopped by rapid removal of medium containing unbound radiolabeled OPN and the cells were washed and solubilized with 2 N NaOH. The radioactivity was measured by gamma counter and the specific binding was calculated by subtracting the non-specific binding from the total binding. The K<sub>d</sub> value was determined by Scatchard analysis using "LIGAND" computer program (Munson *et al.*, (1980) Anal.  
15 Biochem. 107:220-239). <sup>125</sup>I-OPN was incubated with CASMC using increasing concentrations of unlabeled OPN at 37°C for 3 h. The results are shown in Figure 1B, *panel b*. The data were an average of duplicate experiments.

For affinity crosslinking experiments, sub-confluent CASMCs were incubated with <sup>125</sup>I-OPN (6.6 x 10<sup>5</sup> cpm/well) in 1 ml of HBSS, pH 7.6 containing 0.1% BSA in  
20 the absence or presence of unlabeled OPN or GRGDS peptide (1μM) at 37°C for 3 h. After washing, the cells were incubated with 0.20 mM DSS in 1 ml HBSS, pH 7.6 at 37°C for 30 min. The cells were scraped, collected by centrifugation and lysed in 40 μl of 1% Triton X-100 solution containing 1 mM PMSF, 20 μg/ml leupeptin and 2 mM EDTA. The supernatants (30 μl) obtained by centrifugation were electrophoresed  
25 as described previously (Laemmli *et al.*, (1970) Nature 227:680-685) and autoradiographed. The results are shown in Figure 1B, *panel a*.

Figure 1B, *panel a*, shows the results of incubation of <sup>125</sup>I-OPN with CASMC in the absence or presence of unlabeled OPN or Gly-Arg-Gly-Asp-Ser (GRGDS) (SEQ ID NO:7) oligopeptide which corresponds to a portion of the cell adhesion sequence of

OPN, and then crosslinked with disuccinimidyl suberate (DSS) (Pierce). These results show that the 300 kD protein band disappeared when the cells were pretreated with either OPN or GRGDS peptide. Furthermore, the 300 kD band was not detected in the absence of DSS.

These results indicate that OPN binds to an approximately 300 kD cell surface protein on CSMCs (Figure 1B, *panel a*) with high specificity and affinity ( $K_d = 1$  nM) (Figure 1C, *panel b*). The results of immunoprecipitation with  $\alpha_v\beta_3$  integrin antibody after binding and affinity-crosslinking of  $^{125}\text{I}$ -OPN with CSMCs established that the approximately 300 kD protein band is indeed  $\alpha_v\beta_3$  integrin.

## 10

## EXAMPLE 2

## Influence of OPN on *In Vitro* Coronary Smooth Muscle Cell Migration, ECM-invasion, And Proliferation

In order to determine the effects of OPN on CASMCs, prior art-accepted *in vitro* assay systems were used to evaluate the effects of this protein on cellular migration, ECM-invasion and proliferation as follows.

### A. CASMC Migration Assay

Migration of CASMC was performed using Transwell cell culture chambers with an 8- $\mu$ M pore size polycarbonate membrane (Costar) as described previously (Yue *et al.*, (1994) Exptl. Cell Res. 214:459-464). Briefly, sub-confluent human CASMC were trypsinized, centrifuged and resuspended in basal medium (SmBM) supplemented with 0.2% BSA. This was followed by the addition of 0.25 ml of cell suspension ( $5 \times 10^4$  cells) to the upper compartment of the chamber. The lower compartment contained 0.5 ml of basal medium supplemented with 0.2% BSA together with 0.68  $\mu$ g/ml OPN, 1.36  $\mu$ g/ml OPN, or buffer alone. After incubation at 37°C for 24 h., the non-migrated cells on the upper surface of the filters were scraped and washed. The migrated cells were fixed in methanol, stained with Giemsa stain, counted

under an inverted microscope and photomicrographed (120 X) using a Zeiss photomicroscope (Axiovert 405 M). In separate experiments, cells in the upper compartment were also treated with monoclonal mouse anti-human  $\alpha_v\beta_3$ -antibody (Chemicon) (10  $\mu\text{g/ml}$ ) before being assayed for migration in order to ascertain whether this OPN-stimulated migration is mediated via  $\alpha_v\beta_3$ . Preimmune IgG treatment served as a non-specific control. The results are shown in Figure 2A.

Figure 2A shows that the rate of migration of CASMCs was enhanced with increasing concentrations of OPN used as chemoattractant. Additionally, the OPN-induced migration was blocked when the cells were pre-treated with  $\alpha_v\beta_3$  integrin-antibody prior to performing each of these assays. A pre-immune IgG, used as a control, failed to exert any inhibitory effect on OPN-induced migration.

#### B. ECM-Invasion Assay

The ECM-invasion assay was performed using a commercially available 24-well matrigel-coated invasion chamber (Collaborative Research) as described previously (Kundu *et al.*, (1996) Proc. Natl. Acad. Sci. (USA) 93:2915-2919). Briefly, the confluent CASMC were trypsinized, centrifuged, and resuspended in basal medium supplemented with 0.1% BSA. The lower compartment of the invasion chamber was filled with fibroblast-conditioned medium (FCM) which served as a chemoattractant. The invasion assays were initiated by inoculating the upper chamber with cells ( $1 \times 10^5/\text{well}$ ) which were either untreated or treated with varying concentrations of OPN (0.5-2.0  $\mu\text{g/ml}$ ). After incubating at 37°C for 24 h, the cells in the upper chamber were discarded, the matrigel was scraped clear and the cells which had invaded the matrigel and migrated to the lower surface of the filter, were fixed, stained, counted and photomicrographed (120X) as described above. The cells were also pre-treated with mouse anti-human  $\alpha_v\beta_3$  antibody (Chemicon) (10  $\mu\text{g/ml}$ ) as described above to determine if the OPN-induced invasion was mediated via  $\alpha_v\beta_3$ . Preimmune IgG was used as a non-specific control. The results are shown in Figure 2B.

The results show that OPN-treatment of the cells enhanced their invasiveness (Figure 2B) when tested on "MATRIGEL," an artificial ECM, in a dose-dependent

manner. The OPN-induced ECM-invasion was blocked when the cells were pre-treated with  $\alpha_v\beta_3$  integrin-antibody prior to performing each of these assays. A pre-immune IgG, used as a control, failed to exert any inhibitory effect on OPN-induced ECM-invasion.

### 5 C. CASMC Proliferation Assay

Proliferation studies were carried out in the presence of platelet-derived growth factor-AB (PDGF-AB) as it has been suggested that *in vivo* platelet activation may contribute to the pathogenesis of restenosis. CASMCs were cultured as described above and the cells were starved in serum free media for 48 h. The proliferation  
10 assays were performed as described previously (Monfardini *et al.*, (1995) J. Biol. Chem. 270:6628-6638). Briefly, the cells were incubated in the absence or presence of PDGF-AB (100 ng/ml) (Upstate Biotechnology, Lake Placid, NY) and increasing concentrations of OPN (1.0 - 6.0  $\mu$ g/ml) at 37°C for 24 h. In separate experiments, cells were pre-treated with either mouse anti human  $\alpha_v\beta_3$ -antibody (5  $\mu$ g/ml),  
15 preimmune IgG or GRGDS peptide (10 nM) followed by OPN (3.0  $\mu$ g/ml). After 4 h, [3H]thymidine (1  $\mu$ Ci/ml) was added and the cells were maintained in culture for an additional 24 h under the same culture conditions as described previously. After removing the supernatants, the cells were washed with basal medium and lysed in 50% TCA. The acid precipitable cell-bound radioactivity was measured using a scintillation  
20 counter (Beckman). The results are shown in Figure 2C.

Figure 2 C shows that OPN-treatment of CASMCs also stimulated their proliferation in a dose-dependent manner. While PDGF-AB alone had virtually no effect on CASMC proliferation, treatment of these cells with OPN had a dramatic dose-dependent effect when used in conjunction with 100 ng/ml of PDGF-AB (Figure  
25 2C). Treatment of the cells with OPN alone yielded a modest proliferative response.

Interestingly, treatment of CASMCs with Gly-Arg-Gly-Asp-Ser (GRGDS) oligopeptide, or with  $\alpha_v\beta_3$  antibody drastically inhibited OPN-induced proliferation (Figure 2C).

Taken together, these results indicate that OPN gene expression is enhanced in proliferating, compared to contact-inhibited CSMCs, and that treatment of these cells with purified OPN stimulated their motility, ECM-invasion, and proliferation. Moreover, these effects of OPN are transduced via  $\alpha_v\beta_3$  integrin. Importantly, these data also suggest that OPN-antisense sequences may be useful for the inhibition of OPN-mediated effects.

### EXAMPLE 3

#### OPN mRNA and Protein Expression In Human Coronary Atherectomy Tissues

The above-discussed data obtained from *in vitro* investigations on cultured CSMCs raised the possibility that CSMCs which are located *in vivo* on the arterial wall migrate from that location, invade the ECM, and proliferate to cause the occlusion which is associated with the restenosis observed following DCA.

Two questions, on which the prior art is silent, were particularly important. The first was whether a distinction could be made between atherosclerotic and non-atherosclerotic coronary arterial tissues solely on the basis of OPN-mRNA and protein expression patterns. If such was the case, the second question was whether the arterial tissues which produce OPN also express one of its receptors, the  $\alpha_v\beta_3$  integrin. These questions were addressed by the determination of the expression of OPN-mRNA, OPN protein and  $\alpha_v\beta_3$  integrin protein in control and coronary atherectomy tissues from human subjects.

#### A. Atherosclerotic Tissue Expresses $\alpha_v\beta_3$ integrin Protein And Higher Levels of OPN-mRNA And OPN Protein Than Control Tissue

Coronary atherectomy tissues was obtained from 13 DCA-patients i.e., patients who participated in an approved clinical research protocol and in whom directional coronary atherectomy (DCA) was clinically indicated. Informed consent was obtained from all patients in whom atherectomy / angioplasty was clinically indicated. Autopsy specimens of normal coronary arteries from 6 subjects (ages 18 - 68) at autopsy who

died of non-cardiac causes and had no evidence of atherosclerosis served as controls. A summary of profiles of patient and control subjects is presented in Table 1.

	TABLE 1 Profile of Patients* and Controls**		
5	Number of Patients	Age Range	Sex
	13 (DCA-patients)	43-62	2F 11M
	6 (Controls)	18-68	2F 4M

\* Informed consent was obtained after the nature and possible consequences of the atherectomy procedure were explained.

10 \*\* No evidence of coronary atherosclerosis at autopsy: death due to non-cardiac causes.

15 DCA-patient and control tissues were used to detect OPN-mRNA by *in situ* hybridization and RT-PCR,  $\alpha_v\beta_3$  integrin protein by immunofluorescence, and OPN protein by both immunofluorescence and Western blotting. The atherectomy tissue samples, immediately after removal, were divided aseptically into three parts for RNA extraction, Western blot analysis and *in situ* hybridization, respectively. RNase-free equipments and reagents were used for collection and storage of tissues used for *in situ* hybridization and RNA extraction. Control samples obtained at autopsy were prepared under the same conditions.

### 1. *In situ* Hybridization

For *in situ* hybridization, a digoxigenin-labeled oligonucleotide probe derived from the sequence of human OPN cDNA (Figure 5, SEQ ID NO:15) was used as follows. Sections of paraformaldehyde-fixed tissues were placed on ribonuclease-free polylysine-treated glass slides (American Histolabs, Inc.) and *in situ* hybridization was carried out as previously described [Peri et al. (1995) J. Clin. Invest. 96:343-353]. The hOPN probe, hOPN-P<sub>2</sub> (nt 647-608): 5'-TCC ATG TGT GAG GTG ATG TCC TCG TCT GTA GCA TCA GGG T-3') (SEQ ID NO:8), was 3' end-labeled with digoxigenin-11-ddUTP (Boehringer Mannheim) as described previously [Peri et al. (1993) J. Clin. Invest. 92:2099-2109]. The slides were photomicrographed with a Zeiss Axiomat photomicroscope (magnification 400 X). The results of *in situ* hybridization are shown in Figure 3A.

Figure 3A, panels a & b and c & d are bright field photomicrographs of coronary atherectomy and normal coronary artery tissues, respectively. *In situ* hybridization with an OPN probe showed that atherosclerotic tissues obtained from DCA-patients expressed very high levels of OPN-mRNA while it was virtually undetectable in control samples.

### 2. Reverse Transcription Polymerase Chain Reaction

For RT-PCR, reverse transcription of total RNAs from DCA-patients and controls and cDNA amplifications were performed according to the method described previously (Peri et al., (1993) J. Clin. Invest. 92:2099-2109) using the primers described *supra*. The results are shown in Figure 3B. In Figure 3B, panel a, lane S contains RNA from human kidney (Clontech, CA) which was used as a positive control since kidney is known to constitutively synthesize high levels of OPN. Lanes 1-5 contain RNA from autopsy samples of 5 representative control subjects without evidence of coronary artery disease. OPN-mRNA and GAPDH-mRNA are shown (panels a and b).

The results of RT-PCR using total RNA from control (Fig 3B, *panel a: lanes 1-5*) and patient samples (Fig 3B, *panel b: lanes 1-5*) corroborated the *in situ* hybridization results (Fig 3A, *panels a - d*); while OPN-mRNA signal was virtually absent in control tissue, significant levels of OPN-mRNA were detected in tissue from coronary atherectomy samples. The apparent lack of OPN-mRNA in control (autopsy) coronary arteries was not due to degradation of nucleic acids since the strong RT-PCR amplification of mRNA of a house keeping gene, GAPDH, was virtually identical in each of these samples (Figure 3B, bottom, *panels a & b*).

### 3. Immunofluorescence

In order to determine whether the outer (adventitia), middle (media) or the inner (intima) tissue layers of the coronary arteries expressed OPN and  $\alpha_v\beta_3$  integrin, immunofluorescence was performed on both DCA-patient and control tissues using antibodies against OPN (Chacklaparampil *et al.*, (1996) Oncogene 12:1457-1467), human SMC-specific  $\alpha$ -actin monoclonal antibody (clone 1A4) (Sigma), and human  $\alpha_v\beta_3$  integrin (Chemicon). Both SMC-specific  $\alpha$ -actin and  $\alpha_v\beta_3$  integrin were readily detectable in both patients and controls, and the intensity of SMC-specific  $\alpha$ -actin and  $\alpha_v\beta_3$  integrin was also very similar in both controls and patients. In contrast, patient tissues produced a high level of OPN-specific immunofluorescence, while OPN-immunofluorescence was virtually undetectable in the control tissues.

These results demonstrate that control and atherosclerotic tissues express  $\alpha_v\beta_3$  integrin protein and that OPN protein levels are elevated in atherosclerotic tissue. Furthermore, these data also show that expression of OPN and  $\alpha_v\beta_3$  integrin is specific to the smooth muscle layer of coronary arteries of both control and atherosclerotic patients.

### 4. Western Blotting

Western blot analysis was performed as described *supra* in Example 1, and the results are shown in Figure 3C. In Figure 3C, *panel a* shows autopsy samples from 5



apparently normal coronary arteries (*lanes 1-5*). *Panel b* shows samples from 5  
atherectomy patients (*lanes 1-5*). Lane S in *panels a and b* contains purified OPN  
prepared from human milk as previously described [Senger *et al.* (1996) *supra*] which  
was used as a standard. The results of the Western blot analysis showed a virtual lack  
5 of OPN in control tissues (*panel a*: lanes 1-5) compared to the detection of appreciable  
levels of OPN in atherectomy samples (*panel b*: lanes 1-5). The SDS-PAGE and  
Western blotting of patient tissue extracts revealed two distinct OPN bands as noted  
above (*see*, Figure 1A).

#### B. Plasma OPN Levels Are Dramatically Elevated Following Angioplasty

10 Since significantly elevated OPN levels were detected in atherosclerotic tissue  
as shown *supra*, and since OPN is a secreted protein, the effect of DCA on OPN levels  
in blood plasma was investigated. This was achieved by Western blot analysis of  
blood samples collected from DCA patients on the day before the procedure, 24 h  
after, and at weekly intervals for 4 weeks following DCA. Plasma samples which  
15 were prepared for OPN detection as previously described (Senger *et al.*, (1988) *Cancer*  
*Res.* 48:5770-5774) were used for Western blotting using the method described in  
Example 1, *supra*. Equal amounts of total plasma proteins were loaded in each lane  
for electrophoresis. Semi-quantitative, densitometric analysis of the OPN bands in  
Western blots was performed using an LKB Ultrascan LX-800 densitometer. Plasma  
20 samples from healthy individuals, who had no clinical evidence of coronary artery  
disease, served as controls. The results of the Western blot analysis are shown in  
Figure 4.

In Figure 4A, *panel a*, lanes 1-5 contain plasma samples from 5 different  
control patients containing equal amounts of protein as determined by  
25 spectrophotometric determination; lane S contains purified OPN standard. Figure 4A,  
*panel b*, lanes 1-6 contain plasma samples from DCA patients obtained 24 h before the  
procedure; *panel c*, lanes 1-6 contain plasma samples from DCA patients 24 h after the

procedure; *panel d* contains plasma samples from DCA patients obtained 3 weeks after DCA.

The results in Figure 4A showed a dramatic difference in the levels of plasma OPN between controls and DCA patients. Importantly, as shown in *panel a*, the control plasma samples had virtually undetectable levels of OPN (*lanes 1-5*), whereas, those from DCA patients, collected 24 h before the procedure (*P, panel b*), had readily visible OPN bands (*lanes 1-6*). Significantly, plasma OPN levels dramatically increased 24 h after DCA (*panel c*) and remained elevated even 3 weeks after the procedure (*panel d*).

Data obtained from a followup of relative densities of OPN bands, resolved by SDS-PAGE and Western blotting of plasma samples of three representative DCA patients, collected over a 4 week period, is shown in Figure 4B. In Figure 4B, plasma samples were obtained from controls ( $C_1$ ,  $C_2$ , and  $C_3$ ) and patients 24 h before DCA ( $P$ ). The numbers indicate the time in weeks after the procedure.

Surprisingly, the baseline plasma OPN levels of the patients, even before the procedure, were remarkably higher than those of the healthy controls. Moreover, plasma OPN levels showed a significant increase within 24 h following DCA, and these elevated plasma OPN levels were sustained for at least 4 weeks after DCA.

Taken together, the data unambiguously demonstrate (a) expression of  $\alpha_v\beta_3$  integrin protein in CSMCs in the arteries of control and atherosclerotic patients [as detected by immunofluorescence], (b) remarkable elevation in the expression of OPN-mRNA [as detected by *in situ* hybridization and RT-PCR] and OPN protein [as detected by visual inspection and densitometric analysis of Western blots] in CSMCs in the arteries of patients suffering from coronary atherosclerosis as compared to healthy individuals, (c) remarkable sustained elevation of OPN protein levels in the serum of arterial atherosclerotic patients following DCA procedure as compared to the levels in healthy controls and to atherosclerotic patients who did not undergo DCA.

**EXAMPLE 4**

*In Vitro* Lipofection of Human Coronary Artery  
Smooth Muscle Cells With Antisense OPN Sequences

5 In order to determine the efficacy of antisense OPN oligonucleotides in the treatment of restenosis, antisense oligonucleotides designed to bind to mRNA encoded by the human OPN gene sequence were synthesized as phosphorothioate-oligonucleotides and their effect *in vitro* on the migration and proliferation of human coronary arterial smooth muscle cells, and on the expression of OPN in these cells was determined.

10 **A. Design And Synthesis of Antisense OPN Sequences**

Five antisense OPN sequences were designed to bind to sequences within the coding region of the human OPN gene sequence depicted in Figure 5 as follows: ASHOPN-P1: 5'-AATCACTGCAATTCTCATGG-3' (SEQ ID NO:9), ASHOPN-P2: 5'-TTAACTGGTATGGCACAGGT-3' (SEQ ID NO:10); ASHOPN-P3: 5'-  
15 AGAACTTCCAGAATCAGCCT-3' (SEQ ID NO:11); ASHOPN-P4: 5'-TCGTTGGACTTACTTGGAAG-3' (SEQ ID NO:12); and ASHOPN-P5: 5'-ATGCTCATTGCTCTCATCAT-3' (SEQ ID NO:13). For each of the antisense sequences, a corresponding control sense sequences was also designed. For the antisense ASHOPN-P1, the corresponding control sense sequence was SHOPN-P6:  
20 5'CCATGAGAATTGCAGTGATT-3' (SEQ ID NO:14). The antisense and sense sequences were synthesized as phosphorothioate-oligonucleotides by GIBCO-BRL (Life Technologies), Gaithersburg, MD.

**B. *In Vitro* Lipofection**

Human coronary artery smooth muscle cells (CASMCs) (Clonetics) were  
25 subjected to lipofection with the antisense sequence ASHOPN-P1 or with the control sense sequence SHOPN-P6, and the effect of lipofection was measured on the

proliferation of the lipofected cells and on the expression of OPN as measured by Western blot analysis.

CASMCs (Clonetics) were transfected with a "LIPOFECTIN"-oligonucleotide complex according to the manufacturer's (GIBCO-BRL Life Technologies, Inc. Gaithersburg, MD) specifications. Briefly, 5 µg of "LIPOFECTIN" was mixed with either 1 or 2 µg of antisense oligonucleotide in 200 µl of serum free medium (SFM) (also called basal medium) and incubated at room temperature for 15 min. Cells ( $1 \times 10^5$  cells /well, 12-well plate) during log phase of growth were washed with SFM and 1 ml of SFM containing Lipofectin with different amounts of antisense S-oligonucleotides was added to each well and mixed by gentle agitation. The cells were incubated further with the same medium at 37°C for 12 h. Additional control cells which received either SFM, or SFM which contained "LIPOFECTIN" alone, were also included. At the end of the 12 h incubation period, cell viability was detected by trypan blue dye exclusion test which showed the cells were healthy. The SFM medium containing "LIPOFECTIN"-oligonucleotide complex was removed, and the cells incubated for an additional 48 h in regular medium. At the end of this incubation period, the cells were ready for the determination of a dose response on OPN expression as measured by Western blotting.

**C. Effect of Lipofection with Antisense OPN Sequences On Migration, Invasion of ECM, Proliferation And OPN Expression**

The effect of antisense ASHOPN-P1 on the proliferation of human coronary artery smooth muscle cells (CASMCs) was determined as described *supra*. Briefly, CASMCs which had been transfected with "LIPOFECTIN" alone, or in the presence of either OPN sense or OPN antisense oligonucleotides (1 µg each) as described above were incubated further using PDGF-AB (100 ng/ml) in the presence or absence of OPN (3 µg/ml) containing basal medium (SFM) for 24 h. After 4 h, [3H]-thymidine (1mCi/ml) was added and the cells were maintained in culture for an additional 24 h under the same culture conditions. The supernatant was removed and the cells washed in basal medium (SFM) and lysed in 50% TCA. The acid precipitable radioactivity

was measured using a scintillation beta counter (Beckman). The results of the proliferation assay are shown in Figure 6.

Figure 6 shows the effect of treatment of human CASCs with "LIPOFECTIN" (5 $\mu$ g/200 $\mu$ l) alone (control), or in the presence of sense sequence, SHOPN-P6 (1.5  $\mu$ g/200ml) or antisense sequence, ASHOPN-P1 (1.5  $\mu$ g/200 $\mu$ l). The results in Figure 6 show that treatment with the antisense ASHOPN-P1 sequence resulted in an 82% inhibition of cell proliferation as compared to cells treated with "LIPOFECTIN" alone, whereas cells treated with the sense sequence, SHOPN, showed about 50% inhibition of proliferation.

The effect of antisense OPN sequences on OPN expression was determined by Western blot analysis as described above. Figure 7 shows the expression of OPN when cells were treated with "LIPOFECTIN" alone or two different doses of S-oligonucleotides antisense OPN sequences (lanes 1-3). Lane 1 contains immunoprecipitates of cells treated with "LIPOFECTIN" alone; Lane 2 contains immunoprecipitates of cells treated with 1  $\mu$ g S-oligonucleotide ASHOPN-P1 (ASHOPN); and Lane 3 contains immunoprecipitates of cells treated with 2  $\mu$ g S-oligonucleotide ASHOPN-P1 (ASHOPN).

The results demonstrate that the antisense sequence ASHOPN-P1 was capable of inhibiting expression of OPN by CASCs and resulted in the inhibition of CASC proliferation and OPN protein expression as compared to either "LIPOFECTIN"-treated cells or to OPN sense-treated cells. Moreover, these results demonstrate that the effect of antisense sequence ASHOPN-P1 is specific.

### EXAMPLE 5

#### Testing Antisense OPN Sequences In A Rat Carotid Artery *In Vivo* Model System

The effect of antisense OPN sequences on restenosis is investigated in an art-accepted rat carotid artery *in vivo* model by local administration of antisense OPN sequences to arteries which had been traumatized by catheterization, followed by the assessment of the effect of treatment on OPN expression and restenosis.

#### A. Administration of antisense OPN to traumatized rat carotid artery

Antisense OPN sequences are administered to traumatized rat carotid arteries via lipofection or as part of a pluronic gel. Traumatization of the rat carotid artery is an art-accepted method for investigating restenosis [Lee et al. (1993) Circulation Research 73:797-807; von der Leyen et al. (1994) FASEB J. 8:A802; Simons et al. (1992) Nature 359:67-70 (1992); Edelman et al. (1992) J. Clin. Invest. 89:465-473; Morishita et al. (1993) Proc. Natl. Acad. Sci. USA 90:8474-8478].

##### 1. Lipofection

In order to traumatize rat arteries, the adventitia of the carotid artery are stripped as previously described [Simons et al. (1992) Nature 359:67-70 (1992); Edelman et al. (1992) J. Clin. Invest. 89:465-473; Morishita et al. (1993) Proc. Natl. Acad. Sci. USA 90:8474-8478] by subjecting the left common carotid arteries of rats to balloon angioplasty which denudes endothelium and induces a highly reproducible intimal migration/proliferation of SMCs over the entire length of the affected blood vessel. Briefly, male Sprague-Dawley rats (average weight 500 g) (Charles Rivers) are anaesthetized with Nembutal (4 mg per 100g), and the left carotid artery of each animal is isolated by a midline cervical incision, suspended on ties and stripped of adventitia. A 2F Fogarty catheter is introduced through the external carotid artery of each rat, advanced to the aortic arch, the balloon is inflated to produce moderate resistance to catheter movement and then gradually withdrawn to the entry point. The entire procedure is repeated three times for each animal. After vascular injury to the carotid artery, the distal injured segment is transiently isolated by temporary ligatures. The oligonucleotide-"LIPOFECTIN" complex (prepared as described *supra*) is infused into the segment and incubated for 15 min at room temperature. After a 15-min incubation, the infusion cannula is removed, and blood flow to the carotid artery is restored by release of the ligatures. Controls receive either "LIPOFECTIN" alone, or a complex of a corresponding sense oligonucleotide-"LIPOFECTIN".

## 2. Pluronic gel

After vascular injury of the carotid artery, the antisense OPN oligonucleotide sequences are added at a concentration of 1 mg ml<sup>-1</sup> to 25% (w/v) solutions of F127 pluronic gels prepared following the manufacturer's (BASF Wyandotte Corporation) instructions, and maintained at 4°C. Prechilled pipettes and tips are used to apply a 200 µl solution to the carotid artery from which the adventitia is stripped. On contact with tissues at 39°C, the solution gels instantaneously generating a translucent layer that envelops the treated region. The wounds are closed immediately after application of the gel, and the rats are returned to their cages. Inspection of additional animals is expected to reveal that pluronic gel disappears over 1-2 h. Controls receive either pluronic gel alone, or pluronic gel containing a corresponding sense sequence.

### B. Effect of treatment with antisense OPN on OPN expression

The effect of antisense treatment on expression of OPN mRNA is determined by Northern analysis of the expression of the previously-described rat osteopontin cDNA sequence (Oldberg *et al.* (1986) Proc. Natl. Acad. Sci. USA 83:8819-8823) (SEQ ID NO:16) shown in Figure 8.

The effect of antisense OPN oligonucleotides in suppressing OPN mRNA levels in the rat carotid artery is investigated 2 weeks after injury when the extent of SMC accumulation has reached a maximum. The treated portion of the blood vessel is surgically removed from five pairs of antisense- and sense-treated rats. It is expected that injured carotid artery treated with antisense oligonucleotide exhibits lowered, or undetectable, levels of OPN mRNA as compared to injured carotid artery treated with sense oligonucleotide.

The effect of antisense treatment on expression of OPN protein is also determined by Western blot analysis according to methods known in the art (Singh *et al.* (1990) J. Biol. Chem. 265:18696-18701; Chakalaparampil *et al.* (1996) Oncogene 12:1457-1467). For Western blot analysis, the treated portion of the blood vessel is surgically removed, and prepared for Western blotting as described above, with the exception that antibody which recognizes rat osteopontin, rather than human

osteopontin, is used. Antibodies which are cross-reactive with rat osteopontin include the previously-described anti-OPN serum (OST-1) as well as the commercially available anti-fibronectin serum (Collaborative Research). OST-1 was raised against the synthetic oligopeptide NH<sub>2</sub>-DPKSKEDDRYLKFRIS-COOH (SEQ ID NO:18),  
5 which represents amino acid residues 291-306 of rat OPN (Singh *et al.* (1990) J. Biol. Chem. 265:1869-1870). OST-1 is cross-reactive with both mouse and human OPNs (Singh *et al.* (1992) J. Biol. Chem. 267:2384-2385). For immunoprecipitation of proteins, aliquots containing equal amounts of trichloroacetic acid-precipitated protein is diluted with 1 volume of RIPA buffer (0.05 M Tris-HCl (pH 7.2), 0.15 M NaCl,  
10 1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS, 100 Kalikrein inactivating units of aprotinin/ml, 5 mM PMSF and 5 µg/ml of trypsin inhibitor) and incubated at 4°C for 2 h with 15 µl of anti-fibronectin or 25 µl of OST-1. The resulting immune complexes are collected by adding an excess (30 µl of 50% slurry in RIPA buffer) of protein A-Sepharose (Pharmacia Biotechnology, Inc.) to the reaction mixture and  
15 incubating for 1 h at 4°C with gentle agitation. The adsorbed immune complexes are pelleted by centrifugation, washed three times with RIPA buffer, twice with PBS, and finally rinsed with distilled water. The immunoprecipitated proteins, s are subsequently suspended in 50 µl of sample buffer (0.07 M Tris-HCl (pH 6.8), 3% SDS, 5% β-mercaptoethanol, 10% glycerol, and 0.01% bromophenol blue). To denature  
20 osteopontin-fibronectin complexes, samples re adjusted to 0.2% SDS, incubated at 95°C for 5 min, diluted with 1 volume of RIPA buffer lacking SDS, and immunoprecipitated with either OST-1 or anti-fibronectin serum. Electrophoretic analysis by SDS-PAGE is then carried out on 10% slab gels.

It is expected that the levels of OPN in injured vessels treated with antisense  
25 will be reduced as compared with OPN levels in injured vessels which have received no treatment or which are treated with carrier (*i.e.*, "LIPOFECTIN" or pluronic gel) alone or with a sense oligonucleotide/carrier complex.



### C. Effect of Treatment with Antisense OPN on Restenosis

The effect of antisense OPN oligonucleotides on restenosis is determined by measurement of vascular DNA synthesis and content, and of the effect on neointimal size.

#### 5 1. Measurement of DNA Synthesis

For bromodeoxyuridine (BrdUrd) staining, BrdUrd is injected into rats after vascular injury (100 mg/kg subcutaneously and 30 mg/kg Intraperitoneally at 18 h prior to sacrifice and then 30 mg/kg intraperitoneally at 12 h prior to sacrifice). Rats are sacrificed on day 4 after the surgical procedure. The carotid artery is removed  
10 after perfusion-fixation (110 mmHg; 1 mmHg = 133 Pa) with 4% (wt/vol) paraformaldehyde and processed for immunohistochemistry by using anti-BrdUrd antibodies (Amersham). The proportion of BrdUrd-positive cells is determined by cell counts under light microscopy in a blinded fashion. Measurement of DNA is performed at 4 days after the surgical procedure using bisbenzimidazole trihydrochloride  
15 (Pierce). It is expected that antisense treatment of injured arteries will inhibit BrdUrd incorporation (a marker of DNA synthesis and cell proliferation) in the vessel wall as compared to the sense-treated controls or to the untreated injured control vessels.

#### 2. Morphometric Analysis

Formation of neointima along the length of the treated artery is determined at  
20 2, 4, and 8 weeks after the surgical procedure. At the time of killing, the animals are anaesthetized with Nembutal and perfused with 150 cc normal saline under a pressure of 120 mm Hg. The carotid arteries are removed, fixed in 3% formalin, and processed for light microscopy in a standard manner. Three individual sections from the middle of surgically treated segments which are treated with antisense sequences are analyzed  
25 by measuring the mean cross-sectional areas of the intimal and of the medial regions which are untreated, treated with carrier (*i.e.*, pluronic gel or "LIPOFECTIN") alone, treated with carrier plus antisense oligonucleotide, or treated with carrier plus sense

oligonucleotide. These measurements are used to determine a ratio of intimal to medial cross-sectional areas. In addition, three sections from the middle section of the injured region which has not received antisense treatment are also analyzed. Animals are coded so that operation and analysis are performed without knowledge of which treatment individual animals receive. It is expected that treatment with antisense will result in a reduction of the cross-sectional ratio of intima/media as compared with the cross-sectional ratio of intima/media in control injured arteries receiving no treatment, carrier alone, or a carrier/sense oligonucleotide complex.

In order to determine the selectivity of the antisense effect, a dose response (*e.g.*, 1  $\mu$ M - 20  $\mu$ M antisense) of the effect on the intimal/medial cross-sectional ratio is determined at the site of oligonucleotide administration. Additionally, the selectivity of the antisense effect is determined by measuring the intimal/medial cross-sectional ratio along the length of the treated vessel in which the site of oligonucleotide administration is marked with silk ties. It is expected that the intimal/medial cross-sectional ratio in injured vessels treated with antisense will be reduced as compared with the ratio in injured vessels which have received no treatment or which are treated with carrier (*i.e.* "LIPOFECTIN" or pluronic gel) alone or with a sense oligonucleotide/carrier complex. Such a reduction in ratio indicates that the antisense molecule is useful in reducing restenosis in a human subject.

As clear from the data presented herein, the present invention has the advantage of providing methods and compositions for preventing and/or treating restenosis. In particular, the OPN antisense sequences are useful in preventing the development of restenosis in angioplasty procedures. Furthermore, OPN antisense sequences provide a tool for specific therapy with minimal potential adverse side-effects in view of the ability of the sequences specifically to target expression of a single gene which is implicated in the development of restenosis. Moreover, OPN antisense sequences as disclosed herein are easy to administer and are effective over a short period of time.

All publications and patents mentioned in the above specification are herein incorporated by reference. Various modifications and variations of the described method and system of the invention will be apparent to those skilled in the art without

departing from the scope and spirit of the invention. Although the invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out  
5 the invention which are obvious to those skilled in the art are intended to be within the scope of the following claims.

## SEQUENCE LISTING

## (1) GENERAL INFORMATION:

- (i) APPLICANT: Mukherjee, Anil B.
- (ii) TITLE OF INVENTION: Methods And Compositions For Treatment Of Restenosis
- (iii) NUMBER OF SEQUENCES: 18
- (iv) CORRESPONDENCE ADDRESS:
  - (A) ADDRESSEE: Medlen & Carroll, LLP
  - (B) STREET: 220 Montgomery Street, Suite 2200
  - (C) CITY: San Francisco
  - (D) STATE: California
  - (E) COUNTRY: United States of America
  - (F) ZIP: 94104
- (v) COMPUTER READABLE FORM:
  - (A) MEDIUM TYPE: Floppy disk
  - (B) COMPUTER: IBM PC compatible
  - (C) OPERATING SYSTEM: PC-DOS/MS-DOS
  - (D) SOFTWARE: PatentIn Release #1.0, Version #1.30
- (vi) CURRENT APPLICATION DATA:
  - (A) APPLICATION NUMBER: US
  - (B) FILING DATE:
  - (C) CLASSIFICATION:
- (viii) ATTORNEY/AGENT INFORMATION:
  - (A) NAME: Carroll, Peter G.
  - (B) REGISTRATION NUMBER: 32,837
  - (C) REFERENCE/DOCKET NUMBER: NIH-05002
- (ix) TELECOMMUNICATION INFORMATION:
  - (A) TELEPHONE: (415) 705-8410
  - (B) TELEFAX: (415) 397-8338

## (2) INFORMATION FOR SEQ ID NO:1:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 20 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: other nucleic acid
  - (A) DESCRIPTION: /desc = "DNA"
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

CTACAACCAG CATATCTTCA

20

## (2) INFORMATION FOR SEQ ID NO:2:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 20 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: other nucleic acid
  - (A) DESCRIPTION: /desc = "DNA"

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

CACCACTCTG ATGAGTCTCA

20

- (2) INFORMATION FOR SEQ ID NO:3:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 20 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: other nucleic acid
  - (A) DESCRIPTION: /desc = "DNA"

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

TCCATGTGTG AGGTGATGTC

20

- (2) INFORMATION FOR SEQ ID NO:4:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 18 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: other nucleic acid
  - (A) DESCRIPTION: /desc = "DNA"

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

CCATGGAGAA GGCTGGGG

18

- (2) INFORMATION FOR SEQ ID NO:5:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 20 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: other nucleic acid
  - (A) DESCRIPTION: /desc = "DNA"

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

CAAAGTTGTC ATGGATGACC

20

- (2) INFORMATION FOR SEQ ID NO:6:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 19 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: other nucleic acid
  - (A) DESCRIPTION: /desc = "DNA"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

CTAAGCAGTT GGTGGTGCA

19

(2) INFORMATION FOR SEQ ID NO:7:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 5 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS: not relevant
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

Gly Arg Gly Asp Ser  
1 5

(2) INFORMATION FOR SEQ ID NO:8:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 40 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid  
(A) DESCRIPTION: /desc = "DNA"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

TCCATGTGTG AGGTGATGTC CTCGTCTGTA GCATCAGGGT

40

(2) INFORMATION FOR SEQ ID NO:9:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 20 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid  
(A) DESCRIPTION: /desc = "DNA"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

AATCACTGCA ATTTCATGG

20

(2) INFORMATION FOR SEQ ID NO:10:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 20 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid  
(A) DESCRIPTION: /desc = "DNA"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:  
TTAACTGGTA TGGCACAGGT 20

(2) INFORMATION FOR SEQ ID NO:11:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 20 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid  
(A) DESCRIPTION: /desc = "DNA"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:  
AGAACTTCCA GAATCAGCCT 20

(2) INFORMATION FOR SEQ ID NO:12:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 20 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid  
(A) DESCRIPTION: /desc = "DNA"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:  
TCGTTGGACT TACTTGGAAG 20

(2) INFORMATION FOR SEQ ID NO:13:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 20 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid  
(A) DESCRIPTION: /desc = "DNA"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:  
ATGCTCATTG CTCTCATCAT 20

(2) INFORMATION FOR SEQ ID NO:14:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 20 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid  
(A) DESCRIPTION: /desc = "DNA"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

CCATGAGAAT TGCAGTGATT

20

(2) INFORMATION FOR SEQ ID NO:15:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1422 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

GACCAGACTC GTCTCAGGCC AGTTGCAGCC TTCTCAGCCA AACCCGACCA AGGAAAACCTC	60
ACTACCATGA GAATTGCAGT GATTTGCTTT TGCCCTCTAG GCATCACCTG TGCCATACCA	120
GTTAAACAGG CTGATTCTGG AAGTTCTGAG GAAAAGCAGC TTTACAACAA ATACCCAGAT	180
GCTGTGGCCA CATGGCTAAA CCCTGACCCA TCTCAGAAGC AGAATCTCCT AGCCCCACAG	240
AATGCTGTGT CCTCTGAAGA AACCAATGAC TTAAACAAG AGACCCTTCC AAGTAAGTCC	300
AACGAAAGCC ATGACCACAT GGATGATATG GATGATGAAG ATGATGATGA CCATGTGGAC	360
AGCCAGGACT CCATTGACTC GAACGACTCT GATGATGTAG ATGACACTGA TGATTCTCAC	420
CAGTCTGATG AGTCTCACCA TTCTGATGAA TCTGATGAAC TGGTCACTGA TTTTCCCACG	480
GACCTGCCAG CAACCGAAGT TTTCCTCCA GTTGTCCCCA CAGTAGACAC ATATGATGGC	540
CGAGGTGATA GTGTGGTTTA TGGACTGAGG TCAAATCTA AGAAGTTTCG CAGACCTGAC	600
ATCCAGTACC CTGATGCTAC AGACGAGGAC ATCACCTCAC ACATGGAAAG CGAGGAGTTG	660
AATGGTGCAT ACAAGGCCAT CCCCCTTGCC CAGGACCTGA ACGCGCCTTC TGATTGGGAC	720
AGCCGTGGGA AGGACAGTTA TGAAACGAGT CAGCTGGATG ACCAGAGTGC TGAAACCCAC	780
AGCCACAAGC AGTCCAGATT ATATAAGCGG AAAGCCAATG ATGAGAGCAA TGAGCATTC	840
GATGTGATTG ATAGTCAGGA ACTTTCCAAA GTCAGCCGTG AATTCCACAG CCATGAATTT	900
CACAGCCATG AAGATATGCT GGTGTAGAC CCCAAAAGTA AGGAAGAAGA TAAACACCTG	960
AAATTTTCGTA TTTCTCATGA ATTAGATAGT GCATCTTCTG AGGTCAATTA AAAGGAGAAA	1020
AAATACAATT TCTCACTTTG CATTTAGTCA AAAGAAAAAA TGCTTTATAG CAAAATGAAA	1080
GAGAACATGA AATGCTCTTT CTCAGTTTAT TGGTTGAATG TGTATCTATT TGAGTCTGGA	1140
AATAACTAAT GTGTTTGATA ATTAGTTTAG TTTGTGGCTT CATGGAAACT CCCTGTAAAC	1200
TAAAAGCTTC AGGGTTATGT CTATGTTTAT TCTATAGAAG AAATGCAAAC TATCACTGTA	1260
TTTTAATATT TGTTATTCTC TCATGAATAG AAATTTATGT AGAAGCAAAC AAAATACTTT	1320



TACCCACTTA AAAAGAGAAT ATAACATTTT ATGTCACTAT AATCTTTTGT TTTTAAAGTT	1380
AGTGTATATT TTGTTGTGAT TATCTTTTTG TGGTGTGAAT AA	1422

(2) INFORMATION FOR SEQ ID NO:16:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1473 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

- ```
(A) NAME/KEY: CDS
(B) LOCATION: 80..1030
```

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

|            |            |            |            |            |            |     |     |     |     |     |     |     |     |     |     |  |     |
|------------|------------|------------|------------|------------|------------|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|--|-----|
| GCAAGCCTCA | GCATCCTTGG | CTTTGCAGTC | TCCTGCGGCA | AGCATTCTCG | AGGAAGCCAG |     |     |     |     |     |     |     |     |     |     |  | 60  |
| CCAAGGACCA | ACTACAACC  | ATG        | AGA        | CTG        | GCA        | GTG | GTT | TGC | CTT | TGC | CTG | TTC |     |     |     |  | 112 |
|            |            | Met        | Arg        | Leu        | Ala        | Val | Val | Cys | Leu | Cys | Leu | Phe |     |     |     |  |     |
|            |            | 1          |            |            |            |     | 5   |     |     |     |     | 10  |     |     |     |  |     |
| GGC        | CTT        | GCC        | TCC        | TGT        | CTC        | CCG | GTG | AAA | GTG | GCT | GAG | TTT | GGC | AGC | TCA |  | 160 |
| Gly        | Leu        | Ala        | Ser        | Cys        | Leu        | Pro | Val | Lys | Val | Ala | Glu | Phe | Gly | Ser | Ser |  |     |
|            |            |            | 15         |            |            |     |     | 20  |     |     |     |     | 25  |     |     |  |     |
| GAG        | GAG        | AAG        | GCG        | CAT        | TAC        | AGC | AAA | CAC | TCA | GAT | GCT | GTA | GCC | ACT | TGG |  | 208 |
| Glu        | Glu        | Lys        | Ala        | His        | Tyr        | Ser | Lys | His | Ser | Asp | Ala | Val | Ala | Thr | Trp |  |     |
|            |            | 30         |            |            |            |     | 35  |     |     |     |     | 40  |     |     |     |  |     |
| CTG        | AAG        | CCT        | GAC        | CCA        | TCT        | CAG | AAG | CAG | AAT | CTT | CTA | GCC | CCA | CAG | AAT |  | 256 |
| Leu        | Lys        | Pro        | Asp        | Pro        | Ser        | Gln | Lys | Gln | Asn | Leu | Leu | Ala | Pro | Gln | Asn |  |     |
|            | 45         |            |            |            |            | 50  |     |     |     |     | 55  |     |     |     |     |  |     |
| TCT        | GTG        | TCC        | TCT        | GAA        | GAA        | ACG | GAT | GAC | TTT | AAG | CAA | GAA | ACT | CTT | CCA |  | 304 |
| Ser        | Val        | Ser        | Ser        | Glu        | Glu        | Thr | Asp | Asp | Phe | Lys | Gln | Glu | Thr | Leu | Pro |  |     |
|            | 60         |            |            |            | 65         |     |     |     |     | 70  |     |     |     |     | 75  |  |     |
| AGC        | AAC        | TCC        | AAT        | GAA        | AGC        | CAT | GAC | CAC | ATG | GAC | GAT | GAT | GAC | GAC | GAC |  | 352 |
| Ser        | Asn        | Ser        | Asn        | Glu        | Ser        | His | Asp | His | Met | Asp | Asp | Asp | Asp | Asp | Asp |  |     |
|            |            |            |            | 80         |            |     |     |     | 85  |     |     |     |     | 90  |     |  |     |
| GAT        | GAC        | GAC        | GGA        | GAC        | CAT        | GCA | GAG | AGC | GAG | GAT | TCT | GTG | AAC | TCG | GAT |  | 400 |
| Asp        | Asp        | Asp        | Gly        | Asp        | His        | Ala | Glu | Ser | Glu | Asp | Ser | Val | Asn | Ser | Asp |  |     |
|            |            |            | 95         |            |            |     | 100 |     |     |     |     |     | 105 |     |     |  |     |
| GAA        | TCT        | GAC        | GAA        | TCT        | CAC        | CAT | TCC | GAT | GAA | TCT | GAT | GAG | TCC | TTC | ACT |  | 448 |
| Glu        | Ser        | Asp        | Glu        | Ser        | His        | His | Ser | Asp | Glu | Ser | Asp | Glu | Ser | Phe | Thr |  |     |
|            |            | 110        |            |            |            |     | 115 |     |     |     |     | 120 |     |     |     |  |     |
| GCC        | AGC        | ACA        | CAA        | GCA        | GAC        | GTT | TTG | ACT | CCA | ATC | GCC | CCC | ACA | GTC | GAT |  | 496 |
| Ala        | Ser        | Thr        | Gln        | Ala        | Asp        | Val | Leu | Thr | Pro | Ile | Ala | Pro | Thr | Val | Asp |  |     |
|            | 125        |            |            |            |            | 130 |     |     |     |     | 135 |     |     |     |     |  |     |
| GTC        | CCT        | GAC        | GGC        | CGA        | GGT        | GAT | AGC | TTG | GCT | TAC | GGA | CTG | AGG | TCA | AAG |  | 544 |
| Val        | Pro        | Asp        | Gly        | Arg        | Gly        | Asp | Ser | Leu | Ala | Tyr | Gly | Leu | Arg | Ser | Lys |  |     |
|            | 140        |            |            |            | 145        |     |     |     |     | 150 |     |     |     |     | 155 |  |     |

|                                                                   |      |
|-------------------------------------------------------------------|------|
| TCC AGG AGT TTC CCT GTT TCT GAT GAA CAG TAT CCC GAT GCC ACA GAT   | 592  |
| Ser Arg Ser Phe Pro Val Ser Asp Glu Gln Tyr Pro Asp Ala Thr Asp   |      |
| 160 165 170                                                       |      |
| GAG GAC CTC ACC TCC CGC ATG AAG AGC CAG GAG TCC GAT GAG GCT ATC   | 640  |
| Glu Asp Leu Thr Ser Arg Met Lys Ser Gln Glu Ser Asp Glu Ala Ile   |      |
| 175 180 185                                                       |      |
| AAG GTC ATC CCA GTT GCC CAG CGT CTG AGC GTG CCC TCT GAT CAG GAC   | 688  |
| Lys Val Ile Pro Val Ala Gln Leu Ser Val Pro Ser Asp Gln Asp       |      |
| 190 195 200                                                       |      |
| AGC AAC GGG AAG ACC AGC CAT GAG TCA AGT CAG CTG GAT GAA CCA AGC   | 736  |
| Ser Asn Gly Lys Thr Ser His Glu Ser Ser Gln Leu Asp Glu Pro Ser   |      |
| 205 210 215                                                       |      |
| GTG GAA ACA CAC AGC CTG GAG CAG TCC AAG GAG TAT AAG CAG AGG GCC   | 784  |
| Val Glu Thr His Ser Leu Glu Gln Ser Lys Glu Tyr Lys Gln Arg Ala   |      |
| 220 225 230 235                                                   |      |
| AGC CAC GAG AGC ACT GAG CAG TCG GAT GCG ATC GAT AGT GCC GAG AAG   | 832  |
| Ser His Glu Ser Thr Glu Gln Ser Asp Ala Ile Asp Ser Ala Glu Lys   |      |
| 240 245 250                                                       |      |
| CCG GAT GCA ATC GAT AGT GCA GAG CGG TCG GAT GCT ATC GAC AGT CAG   | 880  |
| Pro Asp Ala Ile Asp Ser Ala Glu Arg Ser Asp Ala Ile Asp Ser Gln   |      |
| 255 260 265                                                       |      |
| GCG AGT TCC AAA GCC AGC CTG GAA CAT CAG AGC CAC GAG TTT CAC AGC   | 928  |
| Ala Ser Ser Lys Ala Ser Leu Glu His Gln Ser His Glu Phe His Ser   |      |
| 270 275 280                                                       |      |
| CAT GAG GAC AAG CTA GTC CTA GAC CCT AAG AGT AAG GAA GAT GAT AGG   | 976  |
| His Glu Asp Lys Leu Val Leu Asp Pro Lys Ser Lys Glu Asp Asp Arg   |      |
| 285 290 295                                                       |      |
| TAT CTG AAA TTC CGC ATT TCT CAT GAA TTA GAG AGT TCA TCT TCT GAG   | 1024 |
| Tyr Leu Lys Phe Arg Ile Ser His Glu Leu Glu Ser Ser Ser Ser Glu   |      |
| 300 305 310 315                                                   |      |
| GTC AAT TAAAGAAGAG GCAAAACCAC AGTTCCTTAC TTTGCTTTAA ATAAAACAAA    | 1080 |
| Val Asn                                                           |      |
| AAGTAAATTC CAACAAGCAG GAATACTAAC TGCTTGTTTC TCAGTTCAGT GGATACATGT | 1140 |
| ATGTGGACAA AGAAATAGAT AGTGTTTTGG GCCCTGAGCT TAGTTCGTTG TTTCATGCAG | 1200 |
| ACACCACTGT AACCTAGAAG TTTCAGCATT TCGCTTCTGT TCTTTCTGTG CAAGAAATGC | 1260 |
| AAATGGCCAC TGCATTTTAA TGATTGCTAT TCTTTTATGA ATAAAATGTA TGTAGAGGCA | 1320 |
| GGCAAACCTTA CAGGAACAGC AAAATTAAAA GAGAACTAT AATAGTCTGT GTCACTATAA | 1380 |
| TCTTTTGGTT TTATAATTAG TGTATATTTT GTTGTGATTA TTTTGTGTTG TGTGAATAAA | 1440 |
| TCTTGTATCT TGAATGTAAA AAAAAAAAAA AAA                              | 1473 |

## (2) INFORMATION FOR SEQ ID NO:17:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 317 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

```

Met Arg Leu Ala Val Val Cys Leu Cys Leu Phe Gly Leu Ala Ser Cys
 1             5             10             15
Leu Pro Val Lys Val Ala Glu Phe Gly Ser Ser Glu Glu Lys Ala His
 20             25             30
Tyr Ser Lys His Ser Asp Ala Val Ala Thr Trp Leu Lys Pro Asp Pro
 35             40             45
Ser Gln Lys Gln Asn Leu Leu Ala Pro Gln Asn Ser Val Ser Ser Glu
 50             55             60
Glu Thr Asp Asp Phe Lys Gln Glu Thr Leu Pro Ser Asn Ser Asn Glu
 65             70             75             80
Ser His Asp His Met Asp Asp Asp Asp Asp Asp Asp Asp Asp Gly Asp
 85             90             95
His Ala Glu Ser Glu Asp Ser Val Asn Ser Asp Glu Ser Asp Glu Ser
100             105             110
His His Ser Asp Glu Ser Asp Glu Ser Phe Thr Ala Ser Thr Gln Ala
115             120             125
Asp Val Leu Thr Pro Ile Ala Pro Thr Val Asp Val Pro Asp Gly Arg
130             135             140
Gly Asp Ser Leu Ala Tyr Gly Leu Arg Ser Lys Ser Arg Ser Phe Pro
145             150             155             160
Val Ser Asp Glu Gln Tyr Pro Asp Ala Thr Asp Glu Asp Leu Thr Ser
165             170             175
Arg Met Lys Ser Gln Glu Ser Asp Glu Ala Ile Lys Val Ile Pro Val
180             185             190
Ala Gln Arg Leu Ser Val Pro Ser Asp Gln Asp Ser Asn Gly Lys Thr
195             200             205
Ser His Glu Ser Ser Gln Leu Asp Glu Pro Ser Val Glu Thr His Ser
210             215             220
Leu Glu Gln Ser Lys Glu Tyr Lys Gln Arg Ala Ser His Glu Ser Thr
225             230             235             240
Glu Gln Ser Asp Ala Ile Asp Ser Ala Glu Lys Pro Asp Ala Ile Asp
245             250             255
Ser Ala Glu Arg Ser Asp Ala Ile Asp Ser Gln Ala Ser Ser Lys Ala
260             265             270

```

Ser Leu Glu His Gln Ser His Glu Phe His Ser His Glu Asp Lys Leu  
 275 280 285

Val Leu Asp Pro Lys Ser Lys Glu Asp Asp Arg Tyr Leu Lys Phe Arg  
 290 295 300

Ile Ser His Glu Leu Glu Ser Ser Ser Ser Glu Val Asn  
 305 310 315

## (2) INFORMATION FOR SEQ ID NO:18:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 16 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS: not relevant
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

Asp Pro Lys Ser Lys Glu Asp Asp Arg Tyr Leu Lys Phe Arg Ile Ser  
 1 5 10 15

## CLAIMS

1. An antisense sequence comprising a nucleic acid sequence complementary to at least a portion of the polynucleotide of SEQ ID NO:15.

5 2. The antisense sequence of Claim 1, wherein said sequence is selected from the group consisting of SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, and SEQ ID NO:13.

3. The antisense sequence of Claim 2, wherein said antisense sequence comprises one or more phosphorothioate linkages.

10 4. The antisense sequence of Claim 3, wherein said sequence is entrapped in a liposome.

5. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and an antisense sequence comprising a nucleic acid sequence complementary to at least a portion of the polynucleotide of SEQ ID NO:15.

15 6. A method of diminishing osteopontin expression, comprising:  
a) providing:  
i) a subject suspected of being capable of developing restenosis in a tissue; and  
ii) an osteopontin antisense sequence complementary of to  
least a portion of the polynucleotide of SEQ ID NO:15; and  
20 b) administering an amount of said sequence to said subject under conditions such that said osteopontin expression is diminished.

7. The method of Claim 6, wherein said subject is undergoing angioplasty.

8. The method of Claim 7, wherein said angioplasty is selected from the group consisting of percutaneous trans-luminal coronary angioplasty and directional coronary atherectomy.

9. The method of Claim 6, wherein said tissue is coronary vascular tissue.

5 10. The method of Claim 9, wherein said coronary vascular tissue is arterial.

11. The method of Claim 6, wherein said osteopontin antisense sequence is selected from the group consisting of SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12 and SEQ ID NO:13.

10 12. The method of Claim 6, wherein said administering is parenteral.

13. The method of Claim 12, wherein said parenteral administering is intraarterial.

14. The method of Claim 13, wherein said intraarterial administering is by using a catheter.

15 15. The method of Claim 14, wherein said catheter is a double balloon catheter.

16. The method of Claim 6, wherein said osteopontin antisense sequence is entrapped in a liposome.

20 17. A method of reducing osteopontin expression in a subject undergoing angioplasty, comprising:

a) providing:

- 5
- i) a subject undergoing angioplasty; and
  - ii) an osteopontin antisense sequence complementary of to  
least a portion of the polynucleotide of SEQ ID NO:15; and
  - b) administering an amount of said sequence to said subject under  
conditions such that osteopontin expression is diminished.

18. The method of Claim 17, wherein said osteopontin antisense sequence is selected from the group consisting of SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12 and SEQ ID NO:13.

10 19. The method of Claim 18, wherein said osteopontin antisense sequence comprises one or more phosphorothioate linkages.

20. The method of Claim 19, wherein said osteopontin antisense sequence is entrapped in a liposome.


21. The method of Claim 20, wherein said administering is substantially contemporaneous with said angioplasty.

15 22. The method of Claim 21, wherein said administering is by using a catheter.


23. The method of Claim 22, wherein said catheter is a double balloon catheter.

Figure 1


A.




B.







B.



C.




Figure 3

A. Patients Controls



Figure 4




Figure 5

```

1  GACCAAGACTC GTCTCAGGCC AGTTGCAGCC TTCTCAGCCA AACCCGACCC AAGGAAAACT CACTACCATG AGAATTGCAG TGAATTGCTT TTGCTCTCTA
101  GGCATCACCCT GTGCCATACC AGTTAAACAG GCTGATTCTG GAAATTTCTG GAAAAAGCAG CTTTACAGCA AATACCCASA TGTGTGTGGC ACATGGCTAA
201  ACCCTGACCC ATCTCAGAAAG CAGAATCTCC TAGCCCCACA GAATGCTGTG TCGTCTGAAG AAACCAATGA CTTTAAACAA GAGACCCCTC CAAGTAAATC
301  CAACGAAAGC CATGACCACA TGGATGATAT GGAATGATAT GATGATGATG ACCATGTGSA GAGCCAGSAC TCCATTGACT CGAACGACTC TGAATGATGA
401  GATGACACTG ATGATTCTCA CCAGTCTGAT GAGTCTCACC ATTCTGATGA ATCTGATGAA CTGGTCACTG ATTTTCCDCA GGAACCTGCC SCAACCGAAG
501  TTTTCACTCC AGTTGTCCCC ACAGTAGACA CATATGATGG CCGAGGTGAT AGTGTGTTT ATGGACTGAG GTCAAAATCT AAGAAGTTTC SCAGACCTGA
601  CATCCAGTAC CCTGATGCTA CAGACGAGGA CATCACTCA CACATGGAAA GCGAGGAGTT GAAATGGTECA TACAAAGCCA TCCCGSTTGC CCAGSACCTG
701  AACGCGCCTT CTGATTGGGA CAGCDSGTGG AAGGACAGTT ATGAAACGAG TCAGCTGGAT GACGAGAGTG CTGAAACCCA CAGCCACAAAG CAGTCCAGAT
801  TATATAAGCG GAAAGCCAAAT GATGAGAGCA ATGAGCAATC GATGTGAT GATGTGAT GATGTGAT GATGTGAT GATGTGAT GATGTGAT GATGTGAT
901  TCACAGCCAT GAAGATATGC TGGTTGTAGA CCCCAGAGT AAGGAAAGAG ATAAACACCT GAAATTTCTT ATTTCTCATG AATTGATAG TGCATCTTCT
1001  GAGGTCAATT AAAAGGAGAA AAAATACAAT TTCTCACTT GCAATTTAGT AAAAGGAAAA ATGCTTTTATA GCAAAATGAA ASAGAACATG AAATGCTTCT
1101  TTCTCAGTTT ATTGGTTGAA TGTGTATCTA TTTGAGTCTG GAAATACTA ATGTGTTTGA TAATTAGTTT AGTTTGTGGC TTGATGAAAA CTCCCTGTAA
1201  ACTAAAAGCT TCAGGGTTAT GTCTATGTTT ATTCTATAGA AGAATGCAAA ACTATCACTG TATTTTAATA TTTGTTATTC TCTCATGAAAT AGAAATTTAT
1301  GTAGAGGCAA ACAAAATACT TTTACCCACT TAAAGAGAGA ATATAACAT TTATGTCACT ATATCTCTTT GTTTTTTAAG TTAGTGTATA TTTTGTGTG
1401  ATTATCTTTT TGTGTGTGTA ATAA

```

Figure 6




Figure 7




Figure 8

|                                                                   |     |
|-------------------------------------------------------------------|-----|
| GCAAGCCTCA GCATCCTTGG CTTTGCAGTC TCCTGCGGCA AGCATTCTCG AGGAAGCCAG | 60  |
| CCAAGGACCA ACTACAACC ATG AGA CTG GCA GTG GTT TGC CTT TGC CTG TTC  | 112 |
| Met Arg Leu Ala Val Cys Leu Cys Leu Phe                           |     |
| 1 5 10                                                            |     |
| GGC CTT GCC TCC TGT CTC CCG GTG AAA GTG GCT GAG TTT GGC AGC TCA   | 160 |
| Gly Leu Ala Ser Cys Leu Pro Val Lys Val Ala Glu Phe Gly Ser Ser   |     |
| 15 20 25                                                          |     |
| GAG GAG AAG GCG CAT TAC AGC AAA CAC TCA GAT GCT GTA GCC ACT TGG   | 208 |
| Glu Glu Lys Ala His Tyr Ser Lys His Ser Asp Ala Val Ala Thr Trp   |     |
| 30 35 40                                                          |     |
| CTG AAG CCT GAC CCA TCT CAG AAG CAG AAT CTT CTA GCC CCA CAG AAT   | 256 |
| Leu Lys Pro Asp Pro Ser Gln Lys Gln Asn Leu Leu Ala Pro Gln Asn   |     |
| 45 50 55                                                          |     |
| TCT GTG TCC TCT GAA GAA ACG GAT GAC TTT AAG CAA GAA ACT CTT CCA   | 304 |
| Ser Val Ser Ser Glu Glu Thr Asp Asp Phe Lys Gln Glu Thr Leu Pro   |     |
| 60 65 70 75                                                       |     |
| AGC AAC TCC AAT GAA AGC CAT GAC CAC ATG GAC GAT GAT GAC GAC GAC   | 352 |
| Ser Asn Ser Asn Glu Ser His Asp His Met Asp Asp Asp Asp Asp Asp   |     |
| 80 85 90                                                          |     |
| GAT GAC GAC GGA GAC CAT GCA GAG AGC GAG GAT TCT GTG AAC TCG GAT   | 400 |
| Asp Asp Asp Gly Asp His Ala Glu Ser Glu Asp Ser Val Asn Ser Asp   |     |
| 95 100 105                                                        |     |
| GAA TCT GAC GAA TCT CAC CAT TCC GAT GAA TCT GAT GAG TCC TTC ACT   | 448 |
| Glu Ser Asp Glu Ser His His Ser Asp Glu Ser Asp Glu Ser Phe Thr   |     |
| 110 115 120                                                       |     |
| GCC AGC ACA CAA GCA GAC GTT TTG ACT CCA ATC GCC CCC ACA GTC GAT   | 496 |
| Ala Ser Thr Gln Ala Asp Val Leu Thr Pro Ile Ala Pro Thr Val Asp   |     |
| 125 130 135                                                       |     |
| GTC CCT GAC GGC CGA GGT GAT AGC TTG GCT TAC GGA CTG AGG TCA AAG   | 544 |
| Val Pro Asp Gly Arg Gly Asp Ser Leu Ala Tyr Gly Leu Arg Ser Lys   |     |
| 140 145 150 155                                                   |     |
| TCC AGG AGT TTC CCT GTT TCT GAT GAA CAG TAT CCC GAT GCC ACA GAT   | 592 |
| Ser Arg Ser Phe Pro Val Ser Asp Glu Gln Tyr Pro Asp Ala Thr Asp   |     |
| 160 165 170                                                       |     |
| GAG GAC CTC ACC TCC CGC ATG AAG AGC CAG GAG TCC GAT GAG GCT ATC   | 640 |
| Glu Asp Leu Thr Ser Arg Met Lys Ser Gln Glu Ser Asp Glu Ala Ile   |     |
| 175 180 185                                                       |     |
| AAG GTC ATC CCA GTT GCC CAG CGT CTG AGC GTG CCC TCT GAT CAG GAC   | 688 |
| Lys Val Ile Pro Val Ala Gln Arg Leu Ser Val Pro Ser Asp Gln Asp   |     |
| 190 195 200                                                       |     |
| AGC AAC GGG AAG ACC AGC CAT GAG TCA AGT CAG CTG GAT GAA CCA AGC   | 736 |
| Ser Asn Gly Lys Thr Ser His Glu Ser Ser Gln Leu Asp Glu Pro Ser   |     |
| 205 210 215                                                       |     |
| GTG GAA ACA CAC AGC CTG GAG CAG TCC AAG GAG TAT AAG CAG AGG GCC   | 784 |
| Val Glu Thr His Ser Leu Glu Gln Ser Lys Glu Tyr Lys Gln Arg Ala   |     |
| 220 225 230 235                                                   |     |

Figure 8 (Continued)

|                                                                    |      |
|--------------------------------------------------------------------|------|
| AGC CAC GAG AGC ACT GAG CAG TCG GAT GCG ATC GAT AGT GCC GAG AAG    | 832  |
| Ser His Glu Ser Thr Glu Gln Ser Asp Ala Ile Asp Ser Ala Glu Lys    |      |
| 240 245 250                                                        |      |
| CCG GAT GCA ATC GAT AGT GCA GAG CGG TCG GAT GCT ATC GAC AGT CAG    | 880  |
| Pro Asp Ala Ile Asp Ser Ala Glu Arg Ser Asp Ala Ile Asp Ser Gln    |      |
| 255 260 265                                                        |      |
| GCG AGT TCC AAA GCC AGC CTG GAA CAT CAG AGC CAC GAG TTT CAC AGC    | 928  |
| Ala Ser Ser Lys Ala Ser Leu His Gln Ser His Glu Phe His Ser        |      |
| 270 275 280                                                        |      |
| CAT GAG GAC AAG CTA GTC CTA GAC CCT AAG AGT AAG GAA GAT GAT AGG    | 976  |
| His Glu Asp Lys Leu Val Leu Asp Pro Lys Ser Lys Glu Asp Asp Arg    |      |
| 285 290 295                                                        |      |
| TAT CTG AAA TTC CGC ATT TCT CAT GAA TTA GAG AGT TCA TCT TCT GAG    | 1024 |
| Tyr Leu Lys Phe Arg Ile Ser His Glu Leu Glu Ser Ser Ser Ser Glu    |      |
| 300 305 310 315                                                    |      |
| GTC AAT TAAAGAAGAG GCAAACCAC AGTTCCTTAC TTTGCTTTAA ATAAAACAAA      | 1080 |
| Val Asn                                                            |      |
| AAGTAAATTC CAACAAGCAG GAATACTAAC TGCTTGTTTC TCAGTTCAGT GGATACATGT  | 1140 |
| ATGTGGACAA AGAAATAGAT AGTGTTTTGG GCCCTGAGCT TAGTTCGTTG TTTCATGCAG  | 1200 |
| ACACCACTGT AACCTAGAAG TTTCAGCATT TCGCTTCTGT TCTTTCTGTG CAAGAAATGC  | 1260 |
| AAATGGCCAC TGCATTTTAA TGATTGCTAT TCTTTTATGA ATAAAATGTA TGTAGAGGCA  | 1320 |
| GGCAAACCTTA CAGGAACAGC AAAATTAAAA GAGAACTAT AATAGTCTGT GTCACATATAA | 1380 |
| TCTTTTGGTT TTATAATTAG TGTATATTTT GTTGTGATTA TTTTGTGTTG TGTGAATAAA  | 1440 |
| TCTTGTATCT TGAATGTAAA AAAAAAAAAA AAA                               | 1473 |





## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>(51) International Patent Classification <sup>6</sup> :</b><br><b>C12N 15/11, A61K 31/70, C07H 21/00 //</b><br><b>A61K 9/127, A61M 25/10</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | <b>A3</b> | <b>(11) International Publication Number:</b> <b>WO 99/07844</b><br><b>(43) International Publication Date:</b> 18 February 1999 (18.02.99)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| <b>(21) International Application Number:</b> PCT/US98/16569<br><b>(22) International Filing Date:</b> 7 August 1998 (07.08.98)<br><b>(30) Priority Data:</b><br>60/054,967 7 August 1997 (07.08.97) US<br><b>(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application</b><br>US 60/054,697 (CIP)<br>Filed on 7 August 1997 (07.08.97)<br><b>(71) Applicant (for all designated States except US):</b> THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health [US/US]; Suite 325, 6011 Executive Boulevard, Rockville, MD 20852-3804 (US).<br><b>(72) Inventors; and</b><br><b>(75) Inventors/Applicants (for US only):</b> MUKHERJEE, Anil, Baran [US/US]; 21120 Georgia Avenue, P.O. Box 136, Brookeville, MD 20833-0136 (US). KUNDU, Gopal, Chandra [IN/US]; Apartment #1812, 1001 Rockville Pike, Rockville, MD 20852 (US). PANDA, Dibyendu, Kumar |           | [IN/CA]; Apartment #20, 3721 Dupuis, Montreal, Quebec 83T 1E5 (CA).<br><b>(74) Agents:</b> CARROLL, Peter, G. et al.; Medlen & Carroll, LLP, Suite 2200, 220 Montgomery Street, San Francisco, CA 94104 (US).<br><b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).<br><b>Published</b><br><i>With international search report.</i><br><i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i><br><b>(88) Date of publication of the international search report:</b><br>17 June 1999 (17.06.99) |
| <b>(54) Title:</b> METHODS AND COMPOSITIONS FOR TREATMENT OF RESTENOSIS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>(57) Abstract</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <p>The present invention provides sequences capable of inhibiting osteopontin (OPN) expression. In particular, the sequences provided herein are antisense osteopontin oligonucleotide sequences. The present invention further provides methods for treating restenosis using antisense osteopontin oligonucleotide sequences. In particular, methods for treating restenosis following vascular surgery (e.g., percutaneous transluminal coronary angioplasty (PCTA) and directional coronary atherectomy (DCA)) by using antisense osteopontin oligonucleotide sequences are provided.</p>                                                                                                                                                                                                                                                                                                                                                                    |           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

|           |                          |           |                                          |           |                                              |           |                          |
|-----------|--------------------------|-----------|------------------------------------------|-----------|----------------------------------------------|-----------|--------------------------|
| <b>AL</b> | Albania                  | <b>ES</b> | Spain                                    | <b>LS</b> | Lesotho                                      | <b>SI</b> | Slovenia                 |
| <b>AM</b> | Armenia                  | <b>FI</b> | Finland                                  | <b>LT</b> | Lithuania                                    | <b>SK</b> | Slovakia                 |
| <b>AT</b> | Austria                  | <b>FR</b> | France                                   | <b>LU</b> | Luxembourg                                   | <b>SN</b> | Senegal                  |
| <b>AU</b> | Australia                | <b>GA</b> | Gabon                                    | <b>LV</b> | Latvia                                       | <b>SZ</b> | Swaziland                |
| <b>AZ</b> | Azerbaijan               | <b>GB</b> | United Kingdom                           | <b>MC</b> | Monaco                                       | <b>TD</b> | Chad                     |
| <b>BA</b> | Bosnia and Herzegovina   | <b>GE</b> | Georgia                                  | <b>MD</b> | Republic of Moldova                          | <b>TG</b> | Togo                     |
| <b>BB</b> | Barbados                 | <b>GH</b> | Ghana                                    | <b>MG</b> | Madagascar                                   | <b>TJ</b> | Tajikistan               |
| <b>BE</b> | Belgium                  | <b>GN</b> | Guinea                                   | <b>MK</b> | The former Yugoslav<br>Republic of Macedonia | <b>TM</b> | Turkmenistan             |
| <b>BF</b> | Burkina Faso             | <b>GR</b> | Greece                                   |           |                                              | <b>TR</b> | Turkey                   |
| <b>BG</b> | Bulgaria                 | <b>HU</b> | Hungary                                  | <b>ML</b> | Mali                                         | <b>TT</b> | Trinidad and Tobago      |
| <b>BJ</b> | Benin                    | <b>IE</b> | Ireland                                  | <b>MN</b> | Mongolia                                     | <b>UA</b> | Ukraine                  |
| <b>BR</b> | Brazil                   | <b>IL</b> | Israel                                   | <b>MR</b> | Mauritania                                   | <b>UG</b> | Uganda                   |
| <b>BY</b> | Belarus                  | <b>IS</b> | Iceland                                  | <b>MW</b> | Malawi                                       | <b>US</b> | United States of America |
| <b>CA</b> | Canada                   | <b>IT</b> | Italy                                    | <b>MX</b> | Mexico                                       | <b>UZ</b> | Uzbekistan               |
| <b>CF</b> | Central African Republic | <b>JP</b> | Japan                                    | <b>NE</b> | Niger                                        | <b>VN</b> | Viet Nam                 |
| <b>CG</b> | Congo                    | <b>KE</b> | Kenya                                    | <b>NL</b> | Netherlands                                  | <b>YU</b> | Yugoslavia               |
| <b>CH</b> | Switzerland              | <b>KG</b> | Kyrgyzstan                               | <b>NO</b> | Norway                                       | <b>ZW</b> | Zimbabwe                 |
| <b>CI</b> | Côte d'Ivoire            | <b>KP</b> | Democratic People's<br>Republic of Korea | <b>NZ</b> | New Zealand                                  |           |                          |
| <b>CM</b> | Cameroon                 |           | Republic of Korea                        | <b>PL</b> | Poland                                       |           |                          |
| <b>CN</b> | China                    | <b>KR</b> | Republic of Korea                        | <b>PT</b> | Portugal                                     |           |                          |
| <b>CU</b> | Cuba                     | <b>KZ</b> | Kazakstan                                | <b>RO</b> | Romania                                      |           |                          |
| <b>CZ</b> | Czech Republic           | <b>LC</b> | Saint Lucia                              | <b>RU</b> | Russian Federation                           |           |                          |
| <b>DE</b> | Germany                  | <b>LI</b> | Liechtenstein                            | <b>SD</b> | Sudan                                        |           |                          |
| <b>DK</b> | Denmark                  | <b>LK</b> | Sri Lanka                                | <b>SE</b> | Sweden                                       |           |                          |
| <b>EE</b> | Estonia                  | <b>LR</b> | Liberia                                  | <b>SG</b> | Singapore                                    |           |                          |

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 98/16569

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N15/11 A61K31/70 C07H21/00 //A61K9/127,A61M25/10

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07K C12N A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages                                                                                                                                                                               | Relevant to claim No.      |
|------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------|
| Y          | HIRKO M K ET AL: "ANTISENSE OLIGONUCLEOTIDES AGAINST FGFR-1, TENASCIN, AND OSTEOPONTIN INHIBIT CANINE VEIN GRAFT MYIONTIMAL HYPERPLASIA" SURGICAL FORUM, vol. 46, 22 October 1995, pages 349-351, XP000579718<br>see the whole document<br>---                   | 1-23                       |
| Y          | LIAW L ET AL: "Osteopontin promotes vascular cell adhesion and spreading and is chemotactic for smooth muscle cells in vitro." CIRCULATION RESEARCH, (1994 FEB) 74 (2) 214-24., XP002100969<br>cited in the application<br>see the whole document<br>---<br>-/-- | 1-3,5,6,<br>9-11,<br>17-19 |



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

### \* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

23 April 1999

Date of mailing of the international search report

06/05/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Andres, S

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 98/16569

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category | Citation of document, with indication, where appropriate, of the relevant passages                                                                                                                                                                                                                               | Relevant to claim No.     |
|----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------|
| Y        | WO 94 26888 A (UNIV LELAND STANFORD JUNIOR) 24 November 1994<br><br>see the whole document<br>---                                                                                                                                                                                                                | 4,7,8,<br>12-16,<br>20-23 |
| A        | LIAW L ET AL: "Neutralizing antibodies directed against osteopontin inhibit rat carotid neointimal thickening after endothelial denudation."<br>ARTERIOSCLEROSIS, THROMBOSIS, AND VASCULAR BIOLOGY, (1997 JAN) 17 (1) 188-93., XP002100970<br>see the whole document<br>---                                      | 1-6,<br>9-11,<br>16-20    |
| A        | GIACHELLI, C. ET AL.: "Osteopontin is elevated during neointima formation in rat arteries and is a novel component of human atherosclerotic plaques."<br>JOURNAL OF CLINICAL INVESTIGATION, (1993) VOL. 92, NO. 4, PP. 1686-1696., XP002100971<br>cited in the application<br>see the whole document<br>---      |                           |
| P,X      | KUNDU G ET AL: "Genetic predictors of coronary restenosis: Potential roles of osteopontin and its receptor gene expression in coronary restenosis after angioplasty."<br>AMERICAN JOURNAL OF HUMAN GENETICS, (OCT 1997) VOL. 61, NO. 4, SUPP. 'S', PP. A312; ABSTRACT 1824, XP002100972<br>see abstract<br>----- | 1,3,<br>6-10,17,<br>19    |

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 98/ 16569

### Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
Remark: Although claims 6-23  
are directed to a method of treatment of the human/animal  
body, the search has been carried out and based on the alleged  
effects of the compound/composition.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such  
an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

### Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all  
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment  
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report  
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is  
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

#### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 98/16569

| Patent document<br>cited in search report | Publication<br>date | Patent family<br>member(s) | Publication<br>date |
|-------------------------------------------|---------------------|----------------------------|---------------------|
| WO 9426888 A                              | 24-11-1994          | US 5821234 A               | 13-10-1998          |
|                                           |                     | CA 2163234 A               | 24-11-1994          |
|                                           |                     | EP 0701609 A               | 20-03-1996          |
|                                           |                     | JP 9507381 T               | 29-07-1998          |
|                                           |                     | US 5869462 A               | 09-02-1999          |
| <hr/>                                     |                     |                            |                     |